Archive for the ‘Lyme Vaccine’ Category

Comparative Diets to Address Chronic Inflammation

Comparative Diets to Address Chronic Inflammation


The following is the first half of a two-part article on nutrition that addresses chronic inflammation.

One of the hallmarks of many chronic diseases and disorders is unresolved inflammation in the body. Chronic inflammation can develop when the immune system’s normal inflammatory response to an implied threat continues unabated rather than turning off once the threat is gone.1

Chronic inflammation is a common link among autoimmune disorders like rheumatoid arthritis, lupus and multiple sclerosis; in cardiovascular disorders that lead to heart attacks and strokes; in neurological disorders such as Alzheimer’s, Parkinson’s and epilepsy; and in mental disorders such as depression and schizophrenia.1 Vaccination has been reported to trigger the development of autoimmune disorders associated with chronic inflammation. 2

Infections and Vaccination: Two Different Kinds of Inflammatory Responses and Immunity

Infections and vaccines stimulate different kinds of inflammatory responses in the body to produce antibodies that confer two different kinds of immunity. Naturally acquired active immunity is attained after a person experiences a viral or bacterial infection and the body mounts an inflammatory response to stimulate the production of antibodies and confers long lasting natural immunity. Artificially acquired immunity, which is not identical to naturally acquired immunity, is attained when a person receives a vaccine and the body mounts an inflammatory response to produce antibodies and confers temporary immunity. Booster doses of vaccines to re-stimulate inflammatory responses are often given to lengthen artificial vaccine acquired immunity. 3

Depending upon various genetic, biological and environmental risk factors, some people do not resolve inflammation either after an infection or vaccination and can develop chronic inflammation in the body that leads to chronic health problems.45 In addition to lab altered viruses and bacteria, there are many recognized toxins in childhood vaccines that either singly or in combination cause inflammation in the brain and other parts of the body, including mercury, aluminum, formaldehyde, MSG, antibiotics, polyethylene glycol (antifreeze), squalene, virus like particles and adventitious agents.67

Acute inflammation is easy to recognize: heat, swelling, pain and redness at the site of injury or infection. Chronic inflammation is not quite so obvious, but there are common symptoms that indicate its presence. Some of the most frequently reported include headaches and brain fog, bloating and other digestive problems, joint pain, rashes, fatigue, weight gain, gum disease and mood issues8—many signs familiar to parents of autistic and/or vaccine-injured children.9

Diets Address Chronic Inflammation in Vaccine-Injured Children

The childhood vaccine schedule used in the U.S. has been questioned as a potential factor in the development of inflammatory chronic brain and immune system disorders in children.10

It is an unfortunate fact that those who question the safety of vaccines often “come to the table” following a firsthand experience with a vaccine reaction… in other words, too late to avoid the potentially devastating impact such a reaction can have on their own life or the life of their child. Since conventional medicine rarely acknowledges the connection between vaccination and chronic brain and immune disorders in children, it can be difficult to know where to turn after a vaccine reaction has occurred and there is often lag time before parents find a supportive network. In the search for healing, one of the first avenues explored by parents and doctors specializing in biomedical and holistic health interventions involves nutrition therapy.

Diet is among the most basic of approaches to addressing chronic inflammation. The connection between diet and the risk for developing inflammatory disorders has been recognized for at least 50 years, though studies have been inconclusive about the role played by specific foods and nutrients.11 Nevertheless, harnessing the power of food often can help counteract a chronic inflammatory process and improve some of the related symptoms.

Dietary Fundamentals for Reducing Inflammation

With all the “named” diets available, it can be daunting to decide which direction to turn. Most anti-inflammatory diets share certain basic tenets: avoid sugar and processed foods; stay away from refined flour, wheat, white foods like pasta, rice and bread; and eliminate unhealthy fats. Foods that are often recommended to reduce inflammation in the body are fresh fruits, dark green leafy vegetables, high-quality proteins like cold-water fish, and healthy fats. Some nutritionists suggest that the so-called nightshade foods, which include tomatoes, eggplant, peppers, goji berries and white potatoes, may trigger inflammation in some people,9 and commercial milk products may also cause inflammation in people who are sensitive to lactose or milk proteins.11

Food additives, including dyes, preservatives and artificial flavorings and sweeteners, and high-fructose corn syrup have been pinpointed as problematic for many children with autism spectrum disorders (ASD)12 and some nutritionists suggest avoiding them when trying to reduce systematic inflammation through dietary changes.

The Difference Is in the Details

Some of the most well known diets that surface in an online search for foods that fight inflammation include: the Gut and Psychology Syndrome (GAPS), Paleo, Mediterranean, Atkins, DASH, TLC, Mayo Clinic, Weight Watchers, Raw Food, Keto, The Zone, Whole30, Autoimmune Protocol, Dr. Hyman’s Detox and Dukan…to name just a few.  The annual U.S. News & World Report review of dietary rankings13 and other reviews14of current diet trends can provide an overview for understanding different dietary approaches.

What Do the Experts Say?

The choice of an “anti-inflammatory” diet that limits foods, which have been identified as “pro-inflammatory,” depends on consideration of individual factors, such as specific food sensitivities, personal taste preferences, or the simple desire to try a dietary regimen that sounds interesting.

According to Harvard University’s HealthWatch, “Choose the right foods, and you may be able to reduce your risk of illness. Consistently pick the wrong ones, and you could accelerate the inflammatory disease process.”15 Included in the HealthWatch list of pro-inflammatory foods that should be avoided to reduce inflammation include:

  • Refined carbohydrates, such as white bread and pastries
  • French fries and other fried foods
  • Soda and other sugar-sweetened beverages
  • Red meat (burgers, steaks) and processed meat (hot dogs, sausage)
  • Margarine, shortening, and lard

Anti-inflammatory foods include:

  • Tomatoes
  • Olive oil
  • Green leafy vegetables, such as spinach, kale, and collards
  • Nuts like almonds and walnuts
  • Fatty fish like salmon, mackerel, tuna, and sardines
  • Fruits such as strawberries, blueberries, cherries, and oranges


For More:  In this talk Cyndi O’Meara discusses challenges with wheat.  Diagnosed with MS, Dr. Terry Wahls received the best standard medicine had to offer. After declining to the point of being in a wheel chair, she took matters into her own hands and learned how to properly fuel her body. Using the lessons she learned at the subcellular level, she used diet to cure her MS and get out of her wheelchair.

VL15 Lyme Vaccine – Another Fraud?  by Dr. Jose Lapenta

Hello friends of the DERMAGIC EXPRESS network brings you another hot topic today with respect to LYME DISEASE or CHRONIC ERYTHEMA MIGRANS ….NEW VACCINE VL15 FOR LYME DISEASE … ANOTHER FRAUD? 
The first thing I will remind you, once again, is that in the year 1998 the FDA approved the LYMErix VACCINE to be used against this disease, based on”TARGET” or “DIANA” the proteins of Surface of the BORRELIA BURGDORFERI denominated OspA. The laboratory responsible for marketing the vaccine was GlaxoSmithKline (GSK).
1,400,000 doses were released, and the adverse effects reported by VAERS (ADVERSE EFFECTS REPORTING SYSTEM), which I published in the article STORYS OF VICTIMS OF THE VACCINE FOR THE LYME DISEASE here you can read them.
The vaccine resulted in the death of at least 229 people, of whom 43 were SUICIDATED 7 months after receiving the 2nd dose. 

The main side effect was ARTHRITIS, especially the patients with HISTOCOMPATIBILITY ANTIGEN CLASS II, HLA DR4, the laboratory omitted this data in the vaccination, ALSO THE VACCINE DETERIORATED the health of the carriers of the DISEASE. The laboratory also omitted this fact. 

At the end, the LYMErix vaccine was discontinued in 2002 for three reasons: 
And again you’ll be wondering why I’m telling you this HISTORY THAT HAS 15 YEARS OF EVOLUTION. I’ll give you the answer clear and precise !!!!
All this I am explaining to you because throughout these 15 years, THE LYME DISEASE has spread widely in the United States and Europe. In 2008, 440,000 new cases were reported in the United States and 85,000 in Europe. Currently, in 2017, 300,000 new cases are reported annually in the United States according to the CDC (Center for Disease Control and Prevention).
On the other hand, as I already explained, LYME DISEASE, due to the biological characteristics of BORRELIA (SPIROCHETA), which becomes “undetectable” to diagnostic tests, has become a health problem in these countries. An antibiotic treatment costs between $20 and $1000, and INSURANCE COMPANIES DO NOT WANT TO KNOW ABOUT CHRONIC DISEASES, BECAUSE THE COST IS VERY HIGH. Crude reality.
Here comes the GHOST of the LIMErix vaccine and a new FRENCH BIOTECHNOLOGY company, named VALNEVA, who proudly presented on April 11, 2017 at the World Congress on Vaccines, the project of a “NEW” vaccine for LYME DISEASE, called With CODE VL15-101. 

The FDA approved on 9 December 2016, the preliminary tests, leaving pending FINAL APPROVAL based on SUCCESS or failure thereof. The study began in 2016 in Europe, Belgium and will be performed this year 2017 in the United States, in 180 healthy people over 40 years (See attached).
HERE I PUT YOU WHAT VALNEVA SAYS ABOUT THE VL15 PROJECT (See attached)===============================================================
“… Valneva’s vaccine candidate is based on OspA, one of the most dominant surface proteins expressed by the bacteria when present in a tick. The target indication for Valneva’s vaccine candidate is the prophylactic active immunization against Lyme disease in children and adults. Valneva’s program is the only active vaccined evelopment program for Lyme disease in the pharmaceutical industry. Valneva intends to initiate a Phase I trial in the US and Europe in 2016 with the primary objectives of evaluating safety and tolerability. Immunogenicity for six OspA serotypes will also be monitored for different dose groups and formulations. Pre-clinical results indicated that Valneva’s vaccine candidate can provide protection against the majority of Borrelia species…”

Excellent project hopefully ALL what they propose and the vaccine be a SUCCESS, but NOW…

1.) WHEN LYMErix was withdrawn the FDA PANEL concluded that the LIMErix vaccine was not associated with the production of ARTHRITIS. This is false. VAERS REPORT 322 cases of ARTHRALGIA associated with the vaccine. And the development of VACCINE-INDUCED ARTHRITIS in HLA patients HLA DR-4, now called LYME ARTHRITIS. 
2.) LYMErix was a SCIENTIFIC “SUCCESS” says valneva in his exposition. This is also FALSE. WHY DOES THE POPULATION REJECT IT? Because of the great side effects !!! Why did the patients wrote to the FDA PRAYING that LYMErix was removed from the market. ? SIMPLY, BECAUSE IT WAS A FAILURE. 
3.) WHY DID VALNEVA not mention the patients who were DISABLED FOR EVER by the LYMErix vaccine and the 229 DEATHS I REPORT THE SAME FDA. ? 
I’m going to tell you why VALNEVA “OMITTED” these data: THE ANSWER IS SIMPLE AND UNIQUE: 
The new vaccine VL15-101 that is being proposed for LYME DISEASE is based on the same immunological concept of LYMErix VACCINE OspA. Surface proteins of BORRELIA BURGORFERI. The rest is history. (see attached)

On the other hand, it is interesting that you know that in your immune system there is the Major Histocompatibility Complex (MHC) and its HLA (Histocompatibility Antigens) Molecules Class I A, B, and C, and CLASS II DR and DQ MOLECULES. This have been studied by geneticists For more than 30 years and numerous DERMATOLOGICAL and NON-DERMATOLOGICAL diseases have been associated with these antigens.
In the case of LYME DISEASE, HLA DR-4 antigen and HLA B-27 have been associated with ARTHRITIS, while other infectious diseases present in a certain person can “detonate” an HLA antigen to express itself and thereby Worsen a PRE-EXISTING illness, or express a NEW ILLNESS. 
The big question is this – Are HLA studies in the population affected by LYME DISEASE being done?  These studies were done before placing the LYMErix vaccine? They are currently being done with volunteers for the “NEW VACCINE VL15?”. 
As a tip I tell you that Australia did a study on 555 dogs looking for BORRELIA BURGDORFERI, and I came to the conclusion that in this area of ​​the planet there is no LYME disease. In Canada they did it in 2013-2014 and it was concluded that BORRELIOSIS is endemic in that country.
On the other hand, it is well known that LYME DISEASE that does not respond well to treatment, becomes CHRONIC and costs are high. AND ALL OF YOU KNOW THAT INSURANCE COMPANIES DO NOT WANT TO PAY. 
Then it is easier, to create a new expectation, A NEW VACCINE 15 YEARS AFTER THE FAILURE OF LYMErix, for two important facts:
Hopefully VALNEVA will do the proper science and not mislead anyone, and the FDA WILL NOT APPROVE THE VACCINE if the proper science is not done.  If it passes the tests WELCOME the new one.
Finally I say the following, VACCINE VL15 is in PHASE I, which means that are testing the SAFETY in people, if it overcomes this obstacle, it will come to Phase II, to prove how well it works PREVENTING LYME disease. Then Phase III, to test it in a broader population RANGE and at different doses.
Cost: about $3 billion. As a note, I tell you that 86% DO NOT PASS the TWO FINAL STAGES, AND 94% of drugs tested on ANIMALS do NOT pass HUMAN tests. So VL15 of valneva has a LONG ROAD to go.
And now I ask you? Are you willing to try a VACCINE while being totally healthy that could trigger in you ANY ILLNESS you would never otherwise suffer? 
Did you know that in your immunological composition are HISTOCOMPATIBILITY ANTIGENS, (HLA) that by a simple incidence can “TRIGGER” unknow disease?
We will be looking forward to this new project and as always I wish the BEST TO THIS COMPANY THAT TRIES TO DEVELOP a new LYMErix or VL15 for LYME disease.
In the references and attachments the facts …
1.) Immunogenetic Markers Definition in Latvian Patients with Lyme Borreliosis and Lyme Neuroborreliosis.
2.) Associations of HLA DR and DQ molecules with Lyme borreliosis in Latvian patients.
3.) The genospecies B. burgdorferi s.l., isolated from ticks and from neurological patients with suspected Lyme borreliosis.
4.) [Critical analysis of reference studies on aluminium-based adjuvants toxicokinetics].
5.) Human-leukocyte antigen class II genes in early-onset obsessive-compulsive disorder.
6.) Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome.
7.) HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.
8.) Searching for Lyme borreliosis in Australia: results of a canine sentinel study.
9.) Canine infection with Borrelia burgdorferi, Dirofilaria immitis, Anaplasma spp. and Ehrlichia spp. In Canada, 2013-2014.
10.) Aluminum vaccine adjuvants: are they safe?
11.) Lyme Disease Testing by Large Commercial Laboratories in the United States 
1.) Immunogenetic Markers Definition in Latvian Patients with Lyme Borreliosis and Lyme Neuroborreliosis.
Kovalchuka L1, Cvetkova S2, Trofimova J3, Eglite J4, Gintere S5, Lucenko I6, Oczko-Grzesik B7, Viksna L8, Krumina A9,10.
Author information 
Institute of Food Safety, Animal Health and Environment BIOR, Riga LV-1076, Latvia.
Institute of Food Safety, Animal Health and Environment BIOR, Riga LV-1076, Latvia.
Institute of Food Safety, Animal Health and Environment BIOR, Riga LV-1076, Latvia.
Laboratory of Clinical Immunology and Immunogenetic, Riga Stradiņš University, Riga LV-1067, Latvia.
Department of Family Medicine, Riga Stradiņš University, Riga LV-1067, Latvia.
Centre for Disease Prevention and Control of Latvia, Riga LV-1005, Latvia.
Department of Infectious Diseases, Medical University of Silesia, 40-055 Katowice, Poland.
Department of Infectology and Dermatology, Riga Stradiņš University, Riga LV-1006, Latvia.
Institute of Food Safety, Animal Health and Environment BIOR, Riga LV-1076, Latvia.
Department of Infectology and Dermatology, Riga Stradiņš University, Riga LV-1006, Latvia. 
The aim of this study was to determine the human leukocyte antigen (HLA)-DRB1 alleles in two groups of patients in Latvia: patients with Lyme borreliosis and patients with Lyme neuroborreliosis. The study included 216 patients with Lyme borreliosis, 29 patients with Lyme neuroborreliosis and 282 control persons. All surveyed persons were residents of Latvia. The HLA-DR genotyping was performed by polymerase chain reaction- sequence specific primer (PCR-SSP). The predisposition to the Lyme borreliosis is associated with the HLA-DRB1*07, -DRB1*17(03), -DRB1*04, -DRB1*15(02) alleles. The allele -DRB1*11(05), -DRB1*14(06) and -DRB1*13(06) were significantly more frequent in controls. In-group with Lyme neuroborreliosis differences were found for the -DRB1*07 and -DRB1*04 alleles, but only HLA-DRB1*07 allele was statistically significant after Bonferroni correction and associated with Lyme neuroborreliosis in Latvian patients.
2.) Associations of HLA DR and DQ molecules with Lyme borreliosis in Latvian patients.
Kovalchuka L1, Eglite J, Lucenko I, Zalite M, Viksna L, Krumiņa A.
Author information 
Riga Stradiņš University, Clinical Immunology and Immunogenetic laboratory, Kronvalda Str 9, Riga, Latvia. 
Many autoimmune diseases are associated with variants of HLA genes such as those encoding the MHC complex. This correlation is not absolute, but may help in understanding of the molecular mechanism of disease. The purpose of this study was to determine HLA-DR,-DQ alleles in Latvian patients with Lyme borreliosis and control (healthy) persons. Case patients and control subjects were similar in age, gender and ethnic heritage and differed only as regards the presence of Borrelia burgdorferi infection. The study included 25 patients with clinical stage – erythema migrans and 30 control (healthy) persons. HLA genotyping was performed by PCR with sequence-specific primers.
The results show difference in HLA-DRB1 alleles distribution between patients and control subjects. The frequencies of HLA-DRB1 *04 (OR 11.24; p < 0.007) and HLA-DRB1 *17 (03) (OR 8.05; p < 0.033) were increased in the Lyme disease patients. And the frequency of allele DRB1*13 (OR 0.12; p < 0.017) was lower in Borreliosis patients and higher in control group. But, significant differences in frequencies of HLA-DQ alleles we did not detect.
HLA predisposition to Lyme borreliosis appears not to be limited to HLA molecules, but some HLA-DR alleles also have a significant influence, and, may have implications in our understanding of pathogenesis of this disease. In particular, HLA-DRB1*04 and DRB1 *17 (03) may contribute to the Lyme borreliosis development in Latvian population.
3.) The genospecies B. burgdorferi s.l., isolated from ticks and from neurological patients with suspected Lyme borreliosis.
Neuro Endocrinol Lett. 2011;32(4):491-5. 
Bazovska S1, Durovska J, Derdakova M, Taragelova V, Pancak J, Zaborska M, Traubner P.
Author information 
Institute of Epidemiology, Comenius University, Bratislava, Slovakia. 
Lyme borreliosis (LB) is the most disseminated tick-borne disease in the Northern hemisphere, and infestation with ticks is one of the essential factors influencing transmission of the disease to humans. This work intends to compare the occurrence of borrelia circulating in indigenous ticks and in patients suffering from neurological diseases.
The total of 660 nymphs and 567 adult ticks from the Bratislava and Košice areas was examined over the years 2001-2004, and the cerebrospinal fluid (CSF) of 82 neurological patients suffering from suspected Lyme borreliosis infection was investigated in the 2007-2009 period, using the polymerase chain reaction method (PCR).
PCR investigation proved presence of borrelia in 23.3% of the total 1227 ticks; of these, co-infection was found in 2.7% of all ticks. Borrelia garinii (9.9%) and B. valaisaina (9.2%) were the prevalent types. PCR investigation of the CSF samples of 32 patients with clinically diagnosed Lyme borreliosis showed the presence of B. burgdorferi s.l. in 17 cases. Positive results were found also in patients with unclear or different diagnoses. In cases where the genospecies could be identified, B. garinii was most frequently found (8x), followed with B. burgdorferi s.s. (4×) and B. afzelii (3×).
The high infestation level of ticks with borrelia, mainly with B. garinii which is the most-often documented borrelia species identified in neurological patients, is indicative of a high risk of this contamination in Slovakia. B. garinii were found also in our neuroborreliosis patients, whereas their proof in the CSF of patients with suspected neuroborreliosis or with a different clinical diagnosis pointed upon their persistence after an infectious experience. However, knowledge of not only the genospecies but also of the genotypes capable of eliciting an invasive disorder would be necessary for better clarification of the relationship between borrelia and their peccant capacity. Identification of the invasive borrelia types circulating in nature, and clarification of the vector vs. human infection incidence relationship is of importance from the aspect of detailed knowledge of the epidemiology of this disease.
4.) [Critical analysis of reference studies on aluminium-based adjuvants toxicokinetics].
Ann Pharm Fr. 2017 May 30. pii: S0003-4509(17)30033-0. doi: 10.1016/j.pharma.2017.04.004. [Epub ahead of print] 
[Article in French]
Masson JD1, Crépeaux G2, Authier FJ1, Exley C3, Gherardi RK4.
Author information 
Inserm U955 E10, centre expert de pathologie neuromusculaire, « Biologie du système neuromusculaire », hôpital Henri-Mondor, faculté de médecine, université Paris-Est-Créteil, 94010 Créteil, France.
Inserm U955 E10, centre expert de pathologie neuromusculaire, « Biologie du système neuromusculaire », hôpital Henri-Mondor, faculté de médecine, université Paris-Est-Créteil, 94010 Créteil, France; École nationale vétérinaire d’Alfort, 7, avenue du Général-de-Gaulle, 94700 Maisons-Alfort, France.
Aluminium and Silicon Research Group, The Birchall Centre, Lennard-Jones Laboratories, Keele University, ST5 5BG, Staffordshire, Royaume-Uni.
Inserm U955 E10, centre expert de pathologie neuromusculaire, « Biologie du système neuromusculaire », hôpital Henri-Mondor, faculté de médecine, université Paris-Est-Créteil, 94010 Créteil, France. Electronic address: 
We reviewed the three reference toxicokinetic studies commonly used to suggest innocuity of aluminum (Al)-based adjuvants. A single experimental study was carried out using isotopic 26Al (Flarend et al., 1997). This study ignored adjuvant cell capture. It was conducted over a short period of time (28 days) and used only two rabbits per adjuvant. At the endpoint, Al retention was 78% for aluminum phosphate and 94% for aluminum hydroxide, both results being incompatible with quick elimination of vaccine-derived Al in urines. Tissue distribution analysis omitted three important retention sites: the injected muscle, the draining lymph node and bone. Two theoretical studies have evaluated the potential risk of vaccine Al in infants, by reference to the oral Minimal Risk Level (MRL) extrapolated from animal studies. Keith et al., 2002 used a too high MRL (2mg/kg/d), an erroneous model of 100% immediate absorption of vaccine Al, and did not consider renal and blood-brain barrier immaturity. Mitkus et al. (2011) only considered absorbed Al, with erroneous calculations of absorption duration. They ignored particulate Al captured by immune cells, which play a role in systemic diffusion and the neuro-inflammatory potential of the adjuvant. MRL they used was both inappropriate (oral Al vs injected adjuvant) and far too high (1mg/kg/d) with regard to experimental studies of Al-induced memory and behavioral changes. Both paucity and serious weaknesses of these studies strongly suggest that novel experimental studies of Al adjuvants toxicokinetics should be performed on the long-term, including post-natal and adult exposures, to ensure innocuity and restore population confidence in Al-containing vaccines.
5.) Human-leukocyte antigen class II genes in early-onset obsessive-compulsive disorder.
Rodriguez N1,2,3, Morer A2,3,4, González-Navarro EA3,5, Gassó P1,3, Boloc D1, Serra-Pagès C3,5,6, Lafuente A1,2,3, Lazaro L2,3,4,7, Mas S1,2,3.
Author information 
a Dept. Anatomic Pathology, Pharmacology and Microbiology , University of Barcelona , Barcelona , Spain.
b Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) , Barcelona , Spain.
c Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain.
d Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences , Hospital Clinic de Barcelona , Barcelona , Spain.
e Immunology Service , Centre de Diagnostic Biomèdic, Hospital Clínic Dept , Barcelona , Spain.
f Dept. Biomedicine , University of Barcelona , Barcelona , Spain.
g Psychiatry and Clinical Psychobiology , University of Barcelona , Barcelona , Spain. 
The exact aetiology of obsessive-compulsive disorder (OCD) is unknown, although there is evidence to suggest a gene-environment interaction model. Several lines of evidence support a possible role of the immune system in this model.
The present study explores the allele variability in HLA genes of class II (HLA-DRB1, HLA-DQB1) in a sample of 144 early-onset OCD compared with reference samples of general population in the same geographical area.
None of the 39 alleles identified (allele frequency >1%) showed significant differences between OCD and reference populations. Pooling the different alleles that comprised HLA-DR4 (including DRB1*04:01, DRB1*04:04 and DRB1*04:05 alleles) we observed a significantly higher frequency (X21 = 5.53, P = 0.018; OR = 1.64, 95% CI 1.08-2.48) of these alleles in the early-onset OCD sample (10.8%) than in the reference population (6.8%).
Taking into account the role of HLA class II genes in the central nervous system, the results presented here support a role of the immune system in the pathophysiological model of OCD.
6.) Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome.
Eur J Clin Microbiol Infect Dis. 2007 Sep;26(9):611-7. 
Seidel MF1, Domene AB, Vetter H.
Author information
The symptoms of Lyme borreliosis are similar to those of a variety of autoimmune musculoskeletal diseases. Persistence of complaints is frequently interpreted as unsuccessful antibiotic treatment of Borrelia-associated infections. However, such refractory cases are rare, and re-evaluation of differential diagnoses helps to avoid the substantial risk of long-term antibiotic therapy. In this study, we analyzed patients who presented to our rheumatology unit with previous suspected or diagnosed Lyme borreliosis. Eighty-six patients from a 3.5-year period were evaluated. The mean age of patients was 49.2 +/- 17.2 years; 60% (n = 52) reported a tick bite and 33% (n = 28) an erythema. Forty-seven percent (n = 39) had positive enzyme-linked immunoassay results and Western blots (Mikrogen, Martinsried, Germany). All but 12 patients had already received antibiotic treatment previously. Nine percent (n = 8) had ongoing or recent Lyme borreliosis. Twenty-nine percent (n = 25) showed clinical symptoms and radiographic changes compatible with degenerative disorders of the cervical and/or lumbar spine. These patients were significantly older when compared to the other patients (59.3 +/- 13.7 years vs 46.1 +/- 17.2 years, p = 0.001). Seventeen percent (n = 16) had arthropathies related to psoriasis or rheumatoid arthritis. Twelve percent (n = 10) were positive for the HLA B27 antigen. Other diseases were less frequent. Six patients (7%) could not be diagnosed conclusively, and four of these patients had negative Borrelia immunoassay results. In conclusion, Borrelia-associated diseases were rare in this study. Differential diagnoses helped to initiate a successful disease-specific therapeutic strategy.
7.) HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.
Clin Microbiol Rev. 2004 Apr;17(2):348-69. 
Colmegna I1, Cuchacovich R, Espinoza LR.
Author information 
Section of Rheumatology, Department of Medicine, LSU Health Science Center, New Orleans, Louisiana 70112, USA. 
Current evidence supports the concept that reactive arthritis (ReA) is an immune-mediated synovitis resulting from slow bacterial infections and showing intra-articular persistence of viable, non-culturable bacteria and/or immunogenetic bacterial antigens synthesized by metabolically active bacteria residing in the joint and/or elsewhere in the body. The mechanisms that lead to the development of ReA are complex and basically involve an interaction between an arthritogenic agent and a predisposed host. The way in which a host accommodates to invasive facultative intracellular bacteria is the key to the development of ReA. The details of the molecular pathways that explain the articular and extra-articular manifestations of the disease are still under investigation. Several studies have been done to gain a better understanding of the pathogenesis of ReA; these constitute the basis for a more rational therapeutic approach to this disease. 
Reactive arthritis (ReA) is defined as a sterile synovitis developing after a distant infection, usually in the genitourinary or gastrointestinal tract. The detection of microbial components (microbial DNA and RNA) in the joints of patients with ReA has led to the reconsideration of this definition (59). Currently, ReA is better defined as an immune-mediated synovitis resulting from slow bacterial infections and showing intra-articular persistence of viable nonculturable bacteria and/or immunogenetic bacterial antigens synthesized by metabolically active bacteria residing in the joint and/or elsewhere in the body. A classification into HLA-B27-associated and nonassociated forms has also been proposed. Post-streptococcal, Lyme, and viral arthritis are HLA-B27 nonassociated and should be described as distinct entities under the general heading of “infection-related arthritides.” 
This article focuses on HLA-B27-associated ReA. This form of ReA belongs to the group of spondyloarthropathies (SpA), is triggered by bacteria (which enter the body through the mucosal surfaces) from the genera Campylobacter, Chlamydia, Salmonella, Shigella, and Yersinia, and is clinically associated with oligoarthritis of the lower limbs and sometimes with urethritis and conjunctivitis.
8.) Searching for Lyme borreliosis in Australia: results of a canine sentinel study.
Parasit Vectors. 2017 Mar 13;10(1):114. doi: 10.1186/s13071-017-2058-z. 
Irwin PJ1,2, Robertson ID3, Westman ME4, Perkins M5, Straubinger RK6.
Author information 
Vector and Water-Borne Pathogen Research Group, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, 6150, Australia.
College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, 6150, Australia.
College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, 6150, Australia.
Sydney School of Veterinary Science, University of Sydney, Sydney, New South Wales, 2006, Australia.
Pymble Veterinary Clinic, Philip Mall, Kendall Street, West Pymble, New South Wales, 2073, Australia.
Department of Infectious Diseases and Zoonoses, Bacteriology and Mycology, Ludwig-Maximilians-University Munich, 80539, Munich, Germany. 
Lyme borreliosis is a common tick-borne disease of the northern hemisphere that is caused by bacterial spirochaetes of the Borrelia burgdorferi (sensu lato) (Bbsl) complex. To date, there has been no convincing evidence for locally-acquired Lyme borreliosis on the Australian continent and there is currently a national debate concerning the nature and distributions of zoonotic tick-transmitted infectious disease in Australia. In studies conducted in Europe and the United States, dogs have been used as sentinels for tick-associated illness in people since they readily contact ticks that may harbour zoonotic pathogens. Applying this principle, we used a combination of serological assays to test dogs living in tick ‘hot spots’ and exposed to the Australian paralysis tick, Ixodes holocyclus, for evidence of exposure to B. burgdorferi (s.l.) antigens and other vector-borne pathogens.
Altogether, 555 dogs from four demographic groups were recruited into this study. One dog had evidence of exposure to Anaplasma spp. but no other dog was positive in screening tests. A total of 122 dogs (22.0%) had a kinetic ELISA (KELA) unit value > 100, and one dog with a high titre (399.9 KELA units) had been vaccinated against B. burgdorferi (sensu stricto) before travelling to Australia. Older dogs and those with a history of tick paralysis were significantly more likely to have a KELA unit value > 100. Line immunoassay analysis revealed moderate-to-weak (equivocal) bands in 27 (4.9%) dogs.
Except for a single dog presumed to have been exposed to Anaplasma platys, infection with Anaplasma spp. B. burgdorferi (s.l.), Ehrlichia spp., and Dirofilaria immitis, was not detected in the cohort of Australian dogs evaluated in this study. These results provide further evidence that Lyme borreliosis does not exist in Australia but that cross-reacting antibodies (false positive results) are common and may be caused by the transmission of other tick-associated organisms.
9.) Canine infection with Borrelia burgdorferi, Dirofilaria immitis, Anaplasma spp. and Ehrlichia spp. In Canada, 2013-2014.
Parasit Vectors. 2017 May 19;10(1):244. doi: 10.1186/s13071-017-2184-7. 
Herrin BH1, Peregrine AS2, Goring J3, Beall MJ3, Little SE4.
Author information 
Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, USA.
Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada.
IDEXX Laboratories, Inc, Westbrook, ME, USA.
Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, USA. 
Canine test results generated by veterinarians throughout Canada from 2013-2014 were evaluated to assess the geographical distribution of canine infection with Borrelia burgdorferi, Dirofilaria immitis, Ehrlichia spp., and Anaplasma spp.
The percent positive test results of 115,636 SNAP® 4Dx® Plus tests from dogs tested were collated by province and municipality to determine the distribution of these vector-borne infections in Canada.
A total of 2,844/115,636 (2.5%) dogs tested positive for antibody to B. burgdorferi. In contrast, positive test results for D. immitis antigen and antibodies to Ehrlichia spp. and Anaplasma spp. were low, with less than 0.5% of dogs testing positive for any one of these three agents nationwide. Provincial seroprevalence for antibodies to B. burgdorferi ranged from 0.5% (Saskatchewan)-15.7% (Nova Scotia); the areas of highest percent positive test results were in proximity to regions in the USA considered endemic for Lyme borreliosis, including Nova Scotia (15.7%) and Eastern Ontario (5.1%). These high endemic foci, which had significantly higher percent positive test results than the rest of the nation (P < 0.0001), were surrounded by areas of moderate to low seroprevalence in New Brunswick (3.7%), Quebec (2.8%), and the rest of Ontario (0.9%), as well as northward and westward through Manitoba (2.4%) and Saskatchewan (0.5%). Insufficient results were available from the westernmost provinces, including Alberta and British Columbia, to allow analysis.
10.) Aluminum vaccine adjuvants: are they safe?
Curr Med Chem. 2011;18(17):2630-7. 
Tomljenovic L1, Shaw CA.
Author information 
Neural Dynamics Research Group, Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, V5Z 1L8, Canada. 
Aluminum is an experimentally demonstrated neurotoxin and the most commonly used vaccine adjuvant. Despite almost 90 years of widespread use of aluminum adjuvants, medical science’s understanding about their mechanisms of action is still remarkably poor. There is also a concerning scarcity of data on toxicology and pharmacokinetics of these compounds. In spite of this, the notion that aluminum in vaccines is safe appears to be widely accepted. Experimental research, however, clearly shows that aluminum adjuvants have a potential to induce serious immunological disorders in humans. In particular, aluminum in adjuvant form carries a risk for autoimmunity, long-term brain inflammation and associated neurological complications and may thus have profound and widespread adverse health consequences. In our opinion, the possibility that vaccine benefits may have been overrated and the risk of potential adverse effects underestimated, has not been rigorously evaluated in the medical and scientific community. We hope that the present paper will provide a framework for a much needed and long overdue assessment of this highly contentious medical issue.
11.) Lyme Disease Testing by Large Commercial Laboratories in the United States 
Alison F. Hinckley Neeta P. Connally James I. Meek Barbara J. Johnson Melissa M. Kemperman Katherine A. Feldman Jennifer L. White Paul S. Mead
Clin Infect Dis (2014) 59 (5): 676-681. 
Published: 30 May 2014 
Large commercial laboratories in the United States were surveyed to determine Lyme disease testing frequency, practices, and results. Approximately 3.4 million tests were conducted in 2008; 62% in accordance with recommendations. We estimate that 288 000 infections occurred among 2.4 million patients from whom samples were submitted.
Background. Laboratory testing is helpful when evaluating patients with suspected Lyme disease (LD). A 2-tiered antibody testing approach is recommended, but single-tier and nonvalidated tests are also used. We conducted a survey of large commercial laboratories in the United States to assess laboratory practices. We used these data to estimate the cost of testing and number of infections among patients from whom specimens were submitted.
Methods. Large commercial laboratories were asked to report the type and volume of testing conducted nationwide in 2008, as well as the percentage of positive tests for 4 LD-endemic states. The total direct cost of testing was calculated for each test type. These data and test-specific performance parameters available in published literature were used to estimate the number of infections among source patients.
Results. Seven participating laboratories performed approximately 3.4 million LD tests on approximately 2.4 million specimens nationwide at an estimated cost of $492 million. Two-tiered testing accounted for at least 62% of assays performed; alternative testing accounted for <3% of assays. The estimated frequency of infection among patients from whom specimens were submitted ranged from 10% to 18.5%. Applied to the total numbers of specimens, this yielded an estimated 240 000 to 444 000 infected source patients in 2008.
Discussion. LD testing is common and costly, with most testing in accordance with diagnostic recommendations. These results highlight the importance of considering clinical and exposure history when interpreting laboratory results for diagnostic and surveillance purposes.


For more:   So …in 1994, the CDC hosted a consensus conference in Dearborn, MI, along with a dozen labs across the country and together they falsified the very definition of Lyme disease by eliminating the neurological, immunosuppressive type which account for 85% of the cases.

If they conveniently ‘determined’ that the 85% group – those with an immunosuppression neurological outcome––simply did NOT exist, then they could claim that their vaccine was 85% effective. With no immunosuppressive, neurological disease to find, then the vaccine would be a hit with the remaining 15% who presented with an arthritic, bad-knee type only. A brilliant marketing scheme at the expense of millions worldwide for the years to come.
You see, you CANNOT create a vaccine for an OspA fungal antigen — the TRUE definition of chronic Lyme. It can’t be done. And the OspA vaccination known as LYMErix caused the same disease from a syringe as it does when you get Lyme disease from a tick bite. LYMErix victim’s immune systems were destroyed by the vaccine because OspA is an endotoxin that causes immunosuppression and subsequent severe neurologic multi-system disease.
So by narrowing the definition and by claiming that only one type of the disease (the bad knee arthritic type) exists, then they could sell a vaccine. Not only that. They were also able to profit by limiting the number of labs that were sanctioned and thereby cornering the market on the patents of a variety of tick borne diseases.
THE FIRST LYME VACCINE WAS A COMPLETE BUST.  In a vile cesspool of conflicts of interest are university patent holders, drug companies, and the FDA itself as another patent holder. It generated 40 million dollars before it was yanked. (2008, Drymon) One doctor stated that 21 patients developed severe arthritis after receiving the LYMERIX vaccine. The biological mechanism hypothesis was that the outer surface protein A (OspA), which was the antigenic component of the LYMErix vaccine, induced autoimmunity in genetically susceptible individuals, including high levels of autoantibody to OspA in their synovial fluid.

Dr. Stricker states:

Another Lyme OspA Vaccine Whitewash
The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine.Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccinees.

Also, I find it highly intriguing that the push here, and always, is for a vaccine; not a cure, not helping patients with pain, not making care accessible and affordable. Just in creating a new cash-cow for a select few.  Patients be damned.


Vaccines Could Contribute to Disease Epidemics Due to Retrovirus Contamination

The vaccine manufacturing process could be contributing to disease epidemics due to retrovirus contamination

Image: The vaccine manufacturing process could be contributing to disease epidemics due to retrovirus contamination

(Natural News) Vaccines are highly controversial, and much of the debate rightly surrounds their connection to autism and their inclusion of mercury and other heavy metals. However, there is another aspect of vaccines that doesn’t get as much attention even though it could have grave repercussions for life on this planet: Retrovirus contamination.

A type of virus whose genes are encoded into RNA rather than DNA, retroviruses function differently than other types of viruses but can be just as devastating. Human retroviruses include HIV and human T-cell lymphotropic virus 1, which has been associated with some leukemias and lymphomas.

All animals have some retroviruses integrated into their genomes, with as much as 15 percent of the human genome believed to be made up of ERV human retroviruses. They contribute to diseases such as cancer, autoimmune diseases, and neuroimmune diseases.

The manufacturing process involved in human and veterinary vaccines uses live animal and human cells to serve as master seed stock. The process was developed before the mechanisms of retroviruses were fully understood, which means that no one was aware of the risks at the time. While many retroviruses are harmless and remain essentially dormant, they become harmful when they are exposed to cells from other species, which is what can happen during the vaccine manufacturing process itself as well as during the administration of vaccines that contain cell components from other species. Incidentally, this is similar to what has been creating problems when researchers try to transplant pig tissues and organs into humans.

As new vaccines were developed in the 1970s, exposure to retroviruses intensified. These retroviruses have now been associated with many of the chronic illnesses modern humans are facing, from cancer and autism to Alzheimer’s and Chronic Fatigue Syndrome. It is believed that as many as 20 million Americans could be infected with retroviruses, but not all of them will go on to develop a serious illness. They can be thought of as sleeping giants, who are only awakened when there is an immune deficiency.

A recent study published in the journal Biologicals outlined how endogenous retroviruses (ERVs) are infecting cats and how the feline retrovirus known as RD-114 has contaminated vaccines for other pets. There are at least two ERVs in cat genomes, and the RD-114 virus is found in a wide range of vaccines for dogs and other animals. In fact, a different study showed that RD-114-related viruses contaminated around a third of the 25 commercial vaccines for dogs and cats tested.

Retrovirus contamination in vaccines widespread

Research scientist Judy A. Mikovits even goes so far as to say that nearly all human vaccines are contaminated with at least one retrovirus, usually from an animal thanks to the animal byproducts used in vaccine creation. Six percent of Americans now have mouse-related retroviruses, for example, and that almost certainly comes from vaccines.

Take the example of the rotavirus vaccines RotaTeq and Rotarix, which made headlines a few years ago when they were found to be contaminated with pig viruses. The problem becomes even worse when multiple vaccines are given in combination, as is often the case with children and infants. Dr. Mikovits points out that one pig retrovirus can cause symptoms similar to AIDS when there is a simultaneous immune system activation, such as concurrent vaccination, creating a “high-risk scenario for disease in humans.”

Vaccines are risky enough when you take retroviruses out of the equation, but this vastly underreported problem could eventually prove to be the biggest danger of vaccines yet.

Sources for this article include:



Lyme/MSIDS can activate the immune system and be that “sleeping giant,” the author points out.  Dr. Lambert has treated a number of young women who fell ill after their HPV vaccination, which seems to have stimulated a latent Lyme infection to reactivate.  Asymptomatic girls after receiving Gardasil activated dormant Bartonella which was confirmed by testing.

More on retroviruses:  What did microbiologist Judy Mikovitz get for exposing retroviruses in vaccines?  She got jailed without a search warrant and publicly demolished by those who can’t stand exposure to the truth.



Another CDC Conflict of Interest – Director Resigns

Scandalous CDC director RESIGNS after caught buying shares of vaccine maker Merck while heading the CDC

Image: Scandalous CDC director RESIGNS after caught buying shares of vaccine maker Merck while heading the CDC

(Natural News) As yet more proof that the CDC functions as little more than an extension of the corrupt vaccine industry, CDC director Dr. Brenda Fitzgerald was forced to resign yesterday following a that exposed her ownership of shares of Big Tobacco companies as well as Merck, a prominent vaccine manufacturer whose products are promoted by the CDC.

The gross conflict of interest didn’t stop there, either: Fitzgerald also purchased shares of junk food companies and a tobacco corporation, according to media reports, all while she was serving as director of the CDC. “Documents revealed Fitzgerald had holdings in Reynolds American, British American Tobacco, Imperial Brands, Philip Morris International, and Altria Group,” reports CNBC.

“Dr. Brenda Fitzgerald had also invested money in food and pharmaceutical companies just one month after taking over the job,” reports the UK Daily Mail.

Yes, the head of the CDC bought tobacco stocks and Big Pharma stocks, even when her own decisions at the CDC were neck-deep in gross conflicts of interest related to public health.(The CDC studies and reports on death and disease related to smoking. The corrupt agency also promotes pro-vaccine propaganda while burying all science that reveals vaccine injuries or adverse events.)

The CDC is in bed with junk food companies, vaccine manufacturers and Big Tobacco

This pattern of corruption and collusion is no surprise, given that the director of the CDC’s Division for Heart Disease and Stroke Prevention was caught pushing pseudoscience nonsense that favored Coca-Cola and PepsiCo. The CDC, it turns out, is in bed with junk food companies, tobacco companies and vaccine manufacturers… all while claiming to be working in the interests of “public health.”

As further proof of that, CNBC reports:

Along with her Japan Tobacco purchases, documents confirm Fitzgerald also bought thousands of dollars of shares in several health-care companies, including Merck & Co, Bayer and Humana, which the U.S. Department of Health and Human Services deemed a conflict of interest…

In other words, the head of the CDC stood to profit from vaccines, medications, tobacco use and “disease profits” reaped by health care companies.

As the World Mercury Project explains:

Both Merck and Bayer have a pattern of wreaking havoc on human health while striving to bury the evidence. Merck, for example, manufactures the top-selling but devastating Gardasil vaccine and used statistical gimmicks and other deceptive tactics to conceal Gardasil’s risks. Whistleblowers also have accused Merck of falsifying its mumps vaccine data. Bayer, too, has a track record of “scandal and marketing fraud,” having once paid out millions to the U.S. government in a medical fraud settlement after admitting to overcharging for Bayer’s antibiotic Cipro. Bayer also settled tens of millions after having persisted in selling contaminated blood products to hemophiliacs. At present, Bayer is poised to close a “mega-deal” to merge with Monsanto, which manufactures the glyphosate-containing herbicide RoundUp—both glyphosate and RoundUp’s other ingredients have been shown to be highly toxic.

As this video explains, the CDC actually owns 56 vaccines and profits from pro-vaccine propaganda:

Natural News vindicated yet again for accurately claiming the CDC is tied to vaccine makers

The bombshell news confirms yet again that Natural News has been right all along in reporting the “corruption and collusion” of the CDC and vaccine makers. On January 26, 2017, Natural News published a story entitled CDC works in collusion with vaccine manufacturers… can you really trust their “fake science?”

As that story explains:

If you’ve ever wondered how the CDC can afford to do all that it does, look no further than the CDC Foundation. The organization describes itself as some kind of liaison between the CDC and the private sector, existing solely for public benefit, but a quick look at their list of corporate partners reveals a much more sordid story; a story of fake science that is being propagated for industry benefit. While studying the rather lengthy list of corporate donors — who also sometimes collaborate with the CDC on their project — one might notice that many of them are pharma companiespesticide makers, and biotech firms.

When one considers the apparent ties the CDC has to Merck — and countless other corporations — it honestly raises doubts for just about anything the federal agency has put their stamp on.

The World Mercury Project adds:

The CDC has its own lengthy history of corruption and deceit and has routinely turned a blind eye to conflicts of interest while it works to “protect the private good.” Although the agency owns 56 patents applicable to vaccines, it has no problem shredding vaccine safety data it doesn’t like, while continuing to serve as the nation’s powerful (and ostensibly “independent”) arbiter of vaccine policy. Julie Gerberding, the doctor who led the CDC from 2002 to 2009 (the time period when the Food and Drug Administration approved Gardasil without proper safety testing), left CDC to become president of Merck Vaccines and subsequently became Merck’s executive vice president for global strategic communications. Gerberding has benefited handsomely from her shares of Merck stock.

Thus, Brenda Fitzgerald’s personal financial stake in companies such as Merck and Bayer only illustrates, in microcosm, the CDC’s longstanding willingness to cozy up to Big Pharma and Big Health Care in defiance of ethics rules.

CDC corruption and collusion with death-causing corporations is now an established fact

With Dr. Fitzgerald’s sudden resignation and credibility implosion, we now have irrefutable proof that top CDC personnel have financial conflicts of interest with with vaccine companies, Big Pharma companies and even junk food companies.This is now an established fact, widely reported across most of the media. (Natural News told you this years ago…)

Watch the CDC lie to Congress about “vaccine safety” in this eye-opening video:

Follow more news on the corruption and criminality of the CDC at Stay informed about the lies and deceptions of the baby-murdering vaccine industry at



And these are the very folks in power over all things Lyme/MSIDS.  Frightening indeed.  CDC scientists expose agency corruption  An anti-trust law suit of $57 million is being prepared against the CDC. They are accused of deliberately suppressing the use of an accurate DNA direct diagnostics for Lyme disease.

After publishing the 2013 article ‘A simple method for the detection of live Borrelia spirochetes in human blood using classical microscopy techniques’, professor Laane was invited to give a lecture at the 2014 Norvect conference in Oslo. I was present at that conference and still remember how nervous he was. The reason was that several medical professors complained to his university. He was threatened with losing his job, if he would speak at the conference.  In fact, he did not literally speak – as you can see in the movie below – but used performing arts to show the slides of the spirochetes. Professor Laane was fired anyway and his laboratory was closed down.  Masters went over the charts with a fine tooth comb and found huge CDC errors. Another contentious point was the arbitrary cut off date imposed by the CDC which did not pick up serious late-stage symptoms. Another was the CDC’s rejection of many positive blood tests performed in its own lab, as well as other lab work showing “motile spirochetes” in nearly 5% of lone star nymphs. Long story short, after numerous revisions, Masters could never sign onto the bastardized study. The CDC had purposely tossed out data and manipulated the results.

The CDC essentially tried blackmailing Masters into signing off on the study before they would let him see the final draft. Refusing the bait, he published a letter of objection in the Journal of Infectious Diseases as well as an article of his own in Missouri Medicine which showed Missouri patients met the CDC surveillance definition for LD and growing evidence that lone star ticks were infected with an unidentified spirochete causing identical symptoms of LD in patients. When the CDC study came out they unbelievably attributed the rashes they labeled STARI to an allergy to tick saliva! In the acknowledgment section of the paper where dozens of folks were thanked, they completely omitted the man who made it all possible – Dr. Ed Masters.  The racketeering scheme to downplay the severity of Lyme disease as identified in the RICO lawsuit should be addressed and documented by the TBD Working Group and not ignored as if this crime does not exist otherwise it will be business as usual at the Centers for Disease Control and we’ll have another thirty years of failure to properly diagnose, treat and control this life-altering infection. 10 points – Suing the Architects of Lyme Policy as Task Force Meets to Review it  And you’ll notice that for information about “chronic Lyme disease” and long-term treatment, the CDC page kicks you to the National Institutes of Health website. If you follow the link, you’ll find the same-old, same-old tripe about how long-term treatment doesn’t help, etc. (Based on three statistically puny studies of “chronic Lyme” the NIH funded years ago.)  Perhaps the CDC is trying to make its ties to the IDSA less glaringly obvious.  The statement “this disease does not occur nationwide” is inaccurate.  According to CDC surveillance reports, Lyme disease has been reported in every U.S. state except Hawaii, and the black-legged tick that transmits Lyme disease has been found in 45 percent of U.S. counties.

“As a result of their speaking out, from 1997 to 2000, more than 50 physicians in New York, New Jersey, Connecticut, Michigan, Oregon, Rhode Island and Texas were investigated, disciplined or had had their licenses removed. Many of these doctors were reported to their medical boards by the insurance defendants,” the complaint states.
The insurers also allegedly reported doctors who were treating chronic Lyme disease to state medical boards, leading many doctors to refuse to treat Lyme disease patients.”  LYMErix did not produce antibodies. It is a fungal antigen. It activates latent herpesviruses, which are basically the main drivers of the MS and Lupus outcomes. And OspA-induced tolerance to similar TLR2-agonists causing the ALS and Chronic Fatigue outcomes (mycoplasma bear OspA-like antigens). LYMErix vaccine (and the Tuberculosis vaccines) all failed because they caused immunosuppression, no antibodies, and they made the victims more susceptible to other infections.  “The goal of officials at the U.S. Centers for Disease Control and Prevention (CDC) is to achieve a 90 percent health care worker vaccination rate by 2020, and a key strategy for meeting this goal is to tie a health care facility’s employee flu vaccination rate to the facility’s Medicare and Medicaid reimbursements from the federal government.”

The Secret X-Files: The Untold History of the Lymerix Vaccine


pexels-photo-356054.jpegWritten by Dr. José Lapenta

Perhaps the first thing you ask is why a Dr. who lives in the Southern HEMISPHERE where this disease does not exist, – because the ticks in this continent, at least in this country are NOT CARRIERS OF THE BORRELIA BURGDORFERI, – giving him so much Importance to LYME DISEASE. 

(I must insert that Lyme has been confirmed in South America:  Here in the U.S., the infamous Speilman maps have ruled like the iron curtain, but they too have been proven faulty: – scroll down to “Legends of the North.”  Lyme is everywhere.  Period.

I’ll give you the answer: I’ll remind you that I’m the son of a dermatologist WHO WAS A GREAT INVESTIGATOR IN THE LEPROSY FIELD: read THE LEPROSY IN CAPE WHITE, AND THE LEPROSY IN THE ISLAND OF PROVIDENCIA. I particularly inherit his LEGACY and I am advocated at this time to give my help and support to both investigators and patients suffering this terrible disease.

As initial information I will tell you that when I publish the article on February 1, 2017 LOOKING FOR A VACCINE FOR LYME DISEASE I do not imagine that after 4 months of published continue in the first place of the most read. This fact led me to think that something is happening with this disease in the NORTHERN HEMISPHERE which is the most affected and I began to investigate more thoroughly the disease and its consequences.

Later published on May 7, 2017 the article THE LYME DISEASE, DEMENTIA AND ALZHEIMER, emphasizing that the late phase of the disease called NEUROBORRELIOSIS may be involved in neurological damage that may contribute to the development of ALZHEIMER AND DEMENTIA.

Remember that the BORRELIA BURGDORFERI, whatever its type, is a SPIROCHETE just like the TREPONEMA PALLIDUM, causal agent of the SYPHILLIS. If we compare both diseases we will have both have 3 STAGES: PRIMARY, SECONDARY AND TERTIARY. In SYPHILLIS THE TERTIARY STAGE is called NEUROSYPHILLIS, in BORRELIOSIS, is called NEUROBORRELIOSIS, both affect the brain.


1.) Abnormal gait.
2.) Blindness.
3.) Confusion, disorientation.
4.) Sudden personality changes.
5.) Changes in mental stability.
6.) Dementia.
7.) Depression.
8.) Headache.
9.) Urinary and fecal incontinence.
10.) Irritability.
11.) Memory problems.
12.) Mood alterations.
13.) Numbness in toes, feet or legs.
14.) Poor concentration.
15.) Psychosis.
16.) Convulsions.
17.) Rigidity in the neck.
18.) Tremors.
19.) Visual disturbances, sign of the pupils of Argyll Robertson.
20.) Muscle weakness.
21.) Abnormal reflexes.
22.) Muscle atrophy.
23.) Muscle contractions.


1.) Transverse Myelitis.
2.) Ankle pain.
3.) Flu-like symptoms.
4.) Eruption.
5.) Peripheral blindness.
6.) Muscle aches.
7.) Inflammation and pain of the joint.
8.) ANA Positive (Anti-Nuclear Antibodies).
9.) Migraines.
10.) Headaches.
11.) General malaise.
12.) Bone pain.
13.) Pain in the body.
14.) Fatigue.
15.) Severe pain in the joints.
16.) Fibromyalgia.
17.) Crisis of paralysis.
18.) Autoimmune reaction.
19.) Burning sensation on the skin.
20.) Swollen feet.
21.) The joints: migratory pain.
22.) Functional incapacity of the hands with pain.
23.) Severe pain: hand, wrist, shoulder, knees, ankles, neck.
24.) Decreased work performance.
25.) Raynaud’s disease (hands).
26.) Cracking of the tips of the fingers.
27.) Depression.
28.) Guillan Barre syndrome.
29.) Polymeric demyelinating chronic inflammatory neuropathy.
30.) Weakness of the legs.
31.) Sensitivity to light and sound.
32.) Headache, sinus and pressure.
33.) Tingling in hands, arms, legs and feet.
34.) Rigidity, weakness and trembling in hands and arms.
35.) Loss of balance.
36.) Dizziness, and an inability to focus / concentrate.
37.) Monthly menstrual migraines that began immediately after the vaccine and continued for 10 months.
38.) Chronic fatigue syndrome.
39.) Neuropathic pain.
40.) Severe sinusitis.
41.) Severe insomnia.
42.) Uncontrolled crying.
43.) Memory failure.
44.) Muscular atrophy and demyelination of the nerves.
45.) Visual markings.
46.) Tendonitis.
47.) Arthritis.

If you analyze both sets of SIGNS AND SYMPTOMS, they are the same, except for CONVULSIONS and URINARY INCONTINENCE that are manifested in NEUROSYPHILLIS.

This means that the LYMERix vaccine causes symptoms similar to NEUROSYPHILLIS, or tertiary syphilis, causes auto antibodies ANA, autoimmune diseases and many more, I am only talking about 12 cases, practically destroyed life in many of them that was TOTALLY HEALTHY. Is incredible!!

Another fact to know is the PATIENTS WHO ARE HLA-DR4, are more likely to manifest reactions to the vaccine LYMERix, this means that in your immunological composition you have an antigenic marker or ALLELE DENOMINATED DR4, which is determined with a blood test and If you are a carrier, the LYMERix vaccine will show more side effects, one of the cases I put here said that the laboratory NEVER SAID THAT ABOUT THE HLA-DR4, AND HE WAS.



ADVERSE EFFECTS: (SEE ATTACHED), in parentheses the number of cases)

1.) ARTHRALGIA (322).
2.) MYALGIA (227).
3.) PAIN (196).
4.) ASTHENIA (167).
5.) FEVER (126).
6.) FLU SYNDROME (124)
8.) RASH (85).






SUMMARIZING: 229 people WERE practically “KILLED” by placing the LYMErix VACCINE, which means: Looking for a solution they found the death.

SUDDENLY you will say, but Dr., that was many years ago between 1998-2.002, more than 15 years have passed, but I brought this subject today because the production of a NEW VACCINE for LYME disease is already underway.

The LYMERix vaccine was based on (Recombinat OspA) a surface protein A of BORRELIA BURGDORFERI and unfortunately was a tremendous failure. There I put all the studies that I found about it. So you can draw your conclusions.

And I end this POST with some quotes from the patients affected by the LYMErix VACCINE:

“…..Smithkline should not be able to destroy people’s lives as they have destroyed mine …”

“… As of May 8, 2000 there were 467 adverse reactions reported to VAERS, and of them 144 had complained of some sort of joint pain. Please do not let this vaccine hurt anymore people. I know SmithKline is trying to get it approved for children, PLEASE DO NOT LET THEM HURT ANYMORE KIDS…”

“….. The FDA let them put this on the market without fully testing it. The longer that this is left on the market, the more people are going to get hurt. Please stop this madness and
take it off the market…”

“….. No one else should ever suffer such profound life changes through the administration of a “safe” vaccine. He would have been far better off to get Lyme Disease than to be incapacitated by something we counted on to protect his health!…”

“….Please stop this vaccine from wrecking more lives! !Respectfully submitted…”


“….. 1. Doctors don’t know how to handle the rash of side effects. 2. Doctors don’t want to feel their at fault for the vaccine causing effects. 3. Patients are suffering because doctors don’t want to deal with Lyme let alone the vaccine…”

They were not even ready for what could happen ….

This review is dedicated to all researchers, doctors and people advocated in the fight against LYME disease, and at the same time it is a warning to LABORATORIES and MANUFACTURERS, that before launching a new vaccine, they will be sure to test it well for not cause harm to patients including death. !!!

In the references and attach the facts.

Greetings to all.

Dr. José Lapenta.

FDA Vaccine Advisory Committee, January 8, 2001. LYMErix vaccine victim’s stories
1.) CASE No 1:
2.) CASE No 2:
3.) CASE No 3
4.) CASE No 4
5.) CASE No 5
6.) CASE No 6
7.) CASE No 7
8.) CASE No 8
9.) CASE No 9
10.) CASE No 10
11.) CASE No. 11
12.) CASE No 12
14.) Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
15.) Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.
16.) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.
17.) Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
18.) Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development.
19.) Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.
20.) Intentions to receive a potentially available Lyme disease vaccine in an urban sample.
FDA Vaccine Advisory Committee, January 8, 2001.
1.) CASE No 1:
To Whom It May Concern:
I am unable to attend the January 3 1 FDA Vaccine Advisory Committee meeting due to a
restrictive condition, , resulting from the Lymerix vaccine. In the spring of
1999, I decided to get the series of Lymerix shots, after, viewing a verv convincing TV
commercial touting the importance of protecting oneself from Lyme Dise:ase. I felt this would be a good thing to take advantage of since I had had numerous bites from the ticks which cause
Lyme Disease.

I was given the fust shot of the series on April 20, 1999. Thirteen days later, I collapsed,
completely paralyzed. Many tests at the hospital confirmed the di&nosis of Transverse Myelitis
– inflammation of the myelin sheath around the spinal cord. After days in Intensive Care at the
hospital, I was transferred to the Rehabilitation Center where I spent six months. After intensive
physical and occupational therapy, some mobility returned, but I am in a wheelchair most of the
time. My life has been drastically changed for the past 21 months. Up to the day I collapsed, I
was constantly on the go with meetings of historical societies and community organizations,
church activities, house tours, dinner parties, exercise classes, bus trips, theater outings, concerts, etc. I used to wear my daughters out, just telling them about all of the running around I did. Iused to be a world traveler, but now because of physical liitations, I stay close to home. I amable to live at home onlv with sunport from family and friends, and a paid nighttime caregiver.

For the first nine months after coming home from the Rehabilitation Center, I required round-
the-clock caregivers.

Prior to the Lymerix vaccine, I was in excellent health and completely independent. I
strongly urge you to take Lymerix off the market to spare others the pain and suffering it can

Very truly yours,
2.) CASE No 2:
My name is

and I have been asked to speak on behalf ofmy daughter,
‘. had a pretty normal childhood and
adolescence until the year 1999. Until that point in time, she had a very
active life. She had a horse that she used for exercise and enjoyment. She
had competed on him in various venues. They enjoyed jumping and dressage.
She volunteered in a therapeutic riding barn and worked with multiply
handicapped children. Her plans were to get her degree in veterinary medicine
and have a small animal practice. She held down a job at a vet’s office and
loved going to work and facing the challenges there.ln the !spring of that
year, I decided to get her the lyme vaccine. She was in contact with various
animals daily and spent a lot of time in the woods with horses. It seemed like
a good idea at the time. She had had a simple case of unconfirmed Lyme
Disease when she was around 12 years old and it seemed to respond to
antibiotics, so I thought Lymerix would be a good idea. My primary doctor
looked over the literature and agreed to give this series of injections. Our
lives have never been the same.

After the 2nd injection, –complained of ankle pain. I took her to an orthopedic
surgeon who couldn’t find anything wrong at the time. We sent her for physical
therapy and gave her medication. She made the best of it and never really got much better. She
had vague complaints of other joints bothering her, but again she kept
plugging along. She developed flulike symptoms, a rash, and woke up on
October 3 1 st, 1999 with peripheral blindness. She was having terrible muscle
aches and joint swelling and pain. We went to many specialists. Finally, we
decided to test her for HLA-dr4 ad lo and behold we had a positive. We also
had a positive ANA. To this day, she continues to test negative for Lyme,
MS, Lupus, Crohn’s Disease and all of the other autoimmune illnesses that
our doctors assumed were the possible cause. Their is no history of juvenile
arthritis in either side of the family. Her arthritis just kept getting worse,
even with treatments of anti inflammatories
and all of the arthritis medications on the market. She spent her entire
senior year at home, too ill to even walk through the hallways and put in a full
day at school. She missed her senior prom and any social activities that a
normal senior in high school participates in. Her horse coulcl not be exercised
or jumped by her for a very long period of time. We have taken -to
many specialists in the New York area. They have no explanations for this
sudden dramatic change in her health except the probability that she had a
reaction to Lymerix which somehow caused an autoimmune reaction (because
of the bodies exposure to OspA). I am not as knowledgeable as this
distinguished panel of experts that I speak-to today, but I krnow one thing
with all of my being. It was Lymerix which somehow had this devastating
affect on my 17 year-old child. I think you have all considered that possibility
before today. Maybe after today you will think it is more than just a
possibility, you will see this drug can have some longlasting,dangerous side
effects. Just remember, I have been told this by many a doctor in the last
year and a half, they can treat and cure Lyme Disease but they cannot cure
an autoimmune arthritis. This is an 18year old who will never again be able to
run to catch a bus, or jump her horse with abandon. Her life will be forever
changed by Lymerix. Please consider this very carefully when making your
decisions about giving this to children.
3.) CASE No 3
To Whom It May Concern,
January 23,200l
In 1999 I was a very healthy 40 year old. Very active with my 10 year
old son, skating, bowling and biking. My only health complaint was
migraines and daily headaches. On May 21 ,I 999 I received the Lymetix
vaccine. With 24 hours I had flu like symptoms, body aches and low
grade fever. I did not think much of it being a nurse and knowing that this
is a common reaction to vaccines. Two weeks after the shot I woke up
and my right elbow was hurting and with a few days the body aches
returned. By the time I went for my second injection I had complained to
my doctor that I was hurting from head to toe and the fatigue was

He did not think it was related to the vaccine, because he had
heard nothing about any adverse reactions. I had the second injection
that day and my life has been a living hell since. Within 48 hours I was in
severe joint and body pain, that has not stopped. I tried seeing doctors
and no one knew anything about this vaccine and the realctions it was
causing. I was diagnosed with CFS, fibromalagia, and was even told it
could be stress from my job. I am a Hospice nurse and love what I do.
For months I went through this pain without any help from1 the medical
field. I wake up in the mornings and my husband has to help me out of
bed because the pain is so severe.

Four times I have been paralyzed,three from my wrist down and once from
my neck down for up to 20 minutes. I am scared that I my wake up
one day and not be able to move ever again.

I have since seen a doctor that told me I have an auto-immune reaction to
the vaccine that is untreatable and incurable. I am presently under the
care of a pain management doctor. If it was not for the medicine I
would not be able to get through my day. I still wake in the mornings with
severe, debilitating pain. I have to keep the pain medicine by my bed to
get up.

I have had very odd occurrences of unexplained symptoms. I have small
areas on my body that become red and feel as if they are burning, like fire,
from the inside. The fatigue is unbearable at times, especially with having a
10 year old. I am unable to enjoy being active with him like before.

I have been in contact with nearly 75 people that have been harmed by
this vaccine. It is destroying peoples life’s. It is hurting our most healthy
population. The population that goes out doors for different activities, they
are now bedridden or in such severe pain they are unable to move about
with daily activities without difficulty.

This reaction is not just hurting a certain age group. I have been contacted
by people from the age of 17 and up. I ask the committee to recommend
that this vaccine be taken off the market before more people are hurt.

As of May 8, 2000 there were 467 adverse reactions reported to VAERS,
and of them 144 had complained of some sort of joint pain. Please do not
let this vaccine hurt anymore people. I know SmithKline is trying to get it
approved for children, PLEASE DO NOT LET THEM HURT ANYMORE
Thank you,
4.) CASE No 4
Su bj:
Lymerix Vaccine
Wednesday, October 11, 2000 9:s 1:04 AM

I know that I am having a reaction to the lymerix vaccine. My nightmare
started with the second shot which I received sometime in 8/99. I had flu
like systems which turned into joint pain which has lasted around a year. I
reiceived the last shot in 7/00 and have been sick ever since. I have such
joint pain that it is hard to even get out of bed some days. I have had every
kind of blood work done that you can imagine. 1 am being treated by a

I have been on prednisone for the last six weeks. In four
weeks he will be starting me on Methotrexate. I was only 36 yrs old when
this whole thing started I just recently turned 37 yrs old and feel like I am
80. I have to young children we live in a high tic area I will never allow them
to have this vaccine. The FDA and my MD should have gave some sort of
warning that is could happen. Also,the adverse reaction form that you have
to fill out is almost impossible to get the information for that. I thought I
was protecting myself from getting

sick I didn’t realize that I was allowing the government and my doctor to
make me sick. 1 just hope some day 1 will feel better. Thank you
5.) CASE No 5
My name is
. and I am HLA-DM positive.
Eighteen months ago I ran five miles a week and worked
out at least an hour a day. I was very healthy and had no
health problems at all.

Within six months of getting the lymerix vaccine, I
couldn’t get out of bed by myself and was in constant
excruciating joint and muscle pain. My joints have started
making snapping sounds. I now get muscle aches in my
legs and I have a hard time walking. My feet feel like they
are on fire and get swollen. There are days when I all I can
do is stay in bed and cry because I am in so much pain.
Every week my body goes thru some other type of pain. It
moves from elbows to the knees to the hips to the leg
muscles. I also get cold spots that move around on my

I have been tested for Lupus, Crohns Disease and MS
and they are negative. Smithkline should not be able to
destroy peoples lives as they have destroyed mine. The
FDA let them put this on the market without fully testing
it. The longer that this is left on the market, the more
people are going to get hurt. Please stop this madness and
take it offthe market.
Thank You,
6.) CASE No 6
January 9, 2001
To whom it may concern,
My name is :-
-My phone number is –

I was diagnosed with Lyme disease on October, 1991 by Doctor –
and was treated with oral antibiotics. In July of 1998, I was reinfected and
was treated by Doctor –
with oral antibiotics. At his suggestion, I had the
LymeRex vaccine on April 23, 1999 (LY 10482 exp. 1 O/21 /99) and the booster on May
24, 1999 (LY 123A9 exp. 2/l 7/00).
After several months, I was experiencing hand pains and a decrease in function. X-rays
of my hands were ordered plus a blood test for HLA-DR4. I tested positive for the auto
immune factor and my Doctor told me not to have the additional booster shot.
I feel that the pains in my hands, wrists, shoulders, knees, ankles and neck are directly
caused by reaction to the LymeRex vaccine. My hands are affected the most, I can
hardly turn faucets, jar covers, door handles, etc. Since I am a realtor, the pains in my
hands and feet are interfering with my job performance.

My Doctor was never notified by Smith Kline to test for the auto Immune blood factor.
He also was unaware that the vaccine should not be administered to people who were
already infected. Why weren’t the Doctors informed by Smith Kline of these limitations?
I would not be experiencing the pain and diminished use of my hands if I had been told
not to take the vaccine.
Sincerely yours,
7.) CASE No 7
January 1,200l
To Whom It May Concern:

I am a positive, determined 40-year old woman who has recently had an extreme medical
setback. I have run three (3) marathons since 1995 and have been in excellent condition ah
of my life. I have played sports in high school, in college, and have continued
to run and bike tremendous distances up until the Fall of 1999.

Please be advised that after receiving my initial Lymerix vaccination in April of 1999 and
my second Lymerix vaccination in May of 1999, I developed the following adverse
In October of 1999 while training for my fourth marathon, I suddeuly became extremely
fatigue and sluggish. I could no longer physically run, as if my legs ‘were knocked out from
under me. I then developed severe joint and muscle pain throughout my entire body in
January of 2000.
My autoimmune system was also greatly affected. I developed full-blown Raynaud’s
Disease in my hands in March of 2000. There has been a total lack of circulation in my
hands and severe cracking in my finger tips. I can no longer tolerabe temperatures below
50 degrees.

I then received my third Lymerix vaccination in May of 2000. I have never felt so
discouraged and depressed over no longer being able to physically exercise! There has been
no improvement with the fatigue and achy joints even though I have been on anti-
inflammatories since May of 2000 and antibiotics since October of 2000.

This has been extremely difficult for me both physically and emotionally. I have always
been healthy and active, and now I can no loner live my live with xest and the way I know
how!. It is totally devastating!
8.) CASE No 8
January 4,2001

In April of 2000, after seeing LymeRix ads on television and a poster in
my doctor’s office, I decided to have the vaccine. Since my husband and I
love many outdoor activities including travelling, gardening, canoeing and
walking in woods with our dogs, I thought the vaccine would protect him as
well. We both had LymeRix in April and May.

In July, he began to have neurological symptoms and weakness, which
were diagnosed in August as Guillain-Barre Syndrome. He was hospitalized
following an electromyography, nerve conduction studies and a spinal tap.
Released to outpatient physical therapy 5 days later, he continued to grow
weaker. In September, he was rediagnosed with Chronic Inflammatory
Demyelinating Polyneuropathy and hospitalized again for 9 days. Despite
continuing medical care and bi-weekly rounds of plasmapheresis treatments,
his condition has continued to deteriorate. A recent repeat of the
electromyography and nerve conduction studies-showed “severe sensory,
motor, axonal and demyelinating neuropathy . . ..In comparison with the
August 2000 study, the neuropathy has increased substantially”.

The .neurologist has reported the disease to VAEXS as a vackine atdverse event.
My husband was director of the training program at the -_.-.For 33 years, he has
earned his living by walking 10 or more miles a day in the performance of his
job responsibilities. His retirement was planned for 2001, so he could have
more time to enjoy his family and hobbies, but he is so profoundly disabled
that he is unable to walk independently, get into bed or the s:hower. Personal
care is accomplished only through great effort. Our plans now revolve solely
around medical appointments and physical therapy.

No one else should ever suffer such profound life changes through the
administration of a “safe” vaccine. He would have been far better off to get
Lyme Disease than to be incapacitated by something we counted on to protect
his health!
9.) CASE No 9
MY name is *
dndIlive~inNorfh f2entdbdima. I am 55
years old and for the last 27 years I have beenan

1 was always pretty healthy and very active with interests and
hobbies that included hunting, fishing, and golf mainly. I am 6 foot 1 and
weighed 210 Ibs. 1 stayed in reasonably good shape Erom activities and
In the spring of 1999 our Department decided to give us LYMErix vaccine
and told us it was safe and ef%ective. After my second shot in August of
1999 I experienced extreme rib soreness and went ‘for a chest X ray, then
developed tennis .elbow, a stiff knee, and sharp pain in my left hip, along
with increasing~weakness in my legs.

By December my legs ached and Ifelt flu like sometimes and had
to rest more than usual. On Jarmary 30,2000 fny health nose-dived to
where I could not function at all. ‘I did-not know what was wrong
with me, but did not consider lyme disease, since we were told
you could .not get lyme disease from the vaccine. My life
fell into a black hole. 1 became super sensitive to light and sound and was
living in a darkened bedroom with earplugs, with occasional blind folded
trips to various doctors to try and get a diagnoses. I thought that I would
die and many times wished that I would because I felt so bad. Finally in
March the Doctors started looking at Lyme disease and I tested positive.

My current health is better Corn the neurological problems. I am still
unable to work, as I have no strength, especially in my legs. Sometimes
my knees hurt and burn like there is liquid fire in them My hips and
shoulders hurt and ache every day. My right index finger is too stiff to
bend and my left thumb hurts. It is obvious that I will suffer for a long
time because I let them inject a foreign substance called LYMErix into my
body If I had know about the HLA-DR4 theory of arthritis or that booster
shots would be needed, you would not be reading this, because I would
not have consented to the vaccine!! Even though my occupations is high
risk, my work area is low risk and not endemic.

Please stop this vaccine from wrecking more lives! !
Respectfully submitted
10.) CASE No 10
January 12,200l

To Whom It May Concern,

This letter is to inform you of my symptoms, tests and treatments since receiving the
Lymerix vaccine in 1999.

I was diagnosed with Lyme disease in October, 1998, after noticing a large red rash on
my right hip in July, 1998. The rash eventually disappeared, but my hip became very
sore and I developed a limp. Hip pain and fatigue were my only symptoms. A western
blot in October, 1998, confirmed Lyme disease. I began taking oral C’efuroxime –
500mg/twice a day for three weeks. At the end of this period, I still had some hip pain so

I was placed on IV Rocephin – 2 grams/day for four weeks. At the end of this time I was
almost pain-free and after several weeks of physical therapy had no pain whatsoever. I
continued symptom free until May, 1999, after the second Lymerix vaccine. The vaccine
was strongly recommended by the infectious disease physician who had treated me for
lyme disease and felt I would be an excellent candidate for the vaccine.

I received the first vaccine on April 12, 1999, and the second on May ‘7, 1999. Due to the
onset of symptoms, I did not receive the third dose. Below are the symptoms I have
experienced since the second vaccine. These symptoms began within :2 weeks of the
second dose.
-Sinus headache and pressure.
-Tingling in my hands, arms, legs and feet. It is worse when I am lying down and can be
so severe in my arms and hands that it wakes me up. It also occurs while showerin&
sneezing yawning or coughing.
-Burning in my knees, legs, feet and arms.
-Pain in my knees and hips
-Stiffness, weakness and trembling in my right hands and arms. Pain in my right wrist.

This is currently my worst symptom. I find activities such as reading, writing, etc., can
cause soreness and burning to develop in my arm and wrist, and tremor as well.
-Pain in the knuckles of my hands.

-A pulsating feeling in my head and arms. A feeling similar to a tremor, but there is no
visible signs of a tremor.-Small exploding burst of pain/heat all over my body. I know
this sounds odd, but it feels somewhat like a bee sting f?om the inside and is very short-
lived. I have experienced this sensation in many areas of my body.

-Lightheadedness, and an inability to focus/concentrate. It almost feels like my
equilibrium is off, however I do not feel dizzy, more like I’m in a fog.
-A slight jerking movement of my body or a part of my limbs as I lay down and rest.
-Monthly menstrual migraines that began immediately after the vaccine and continued for
10 months.
-The sensation of my stomach turning over, however, it is in my head. I know this
sounds unusual, but someone described it that way and it seemed perfect! This feeling
happens when I am lying down and can occur several times. It seems to occur over
several days and then will subside for a few weeks.

I do not experience all of these symptoms simultaneously, they seem to come and go
without any pattern or predictability. They all began after the second dose of the vaccine.
Listed below are the antibiotics I have taken since receiving the second vaccine.
1 l/22/99 – 0 l/28/00 Doxycycline 200mg/day
01/28/00 – 02/10/00 Doxycycline 3OOmg/day – Discontinued due to GI intolerance
02/13/00 – 03/23/00 Keflex
1500 mg/day – Discontinued due: to yeast infections
03/23/00 – 04/12/00 Zithromax
250 mglday
04/12/00 – 04/23/00 Zithromax
500 mg – Twice a week
05/19/00 – 06/29/00 IV Rocephin 6 week IV therapy
At the end of the IV treatment, I still had no improvement. In September, 2000, I saw Dr.
+ I. He is a physician who is treating chronic lyme
disease as a neurotoxin. I completed the treatment below, with’still no improvement.
09/24/00 – 1 O/l 6/00 Cholestyramine
4 grams per scoop/4 times per day
1 O/l 7/00 – 1 O/30/00 Cholestyramine
4 grams per scoop/4 times per day
750 mg/3 times per day
The following tests have been performed:
06/29/99 – MRI of the brain without/with contrast – result: normal
0710 l/99 – Lyme, Western blot. Positive.
07/28/99 – MRI of the brain with attention to the pituitary – result: 2mm microademoma
in the right side of the pituitary gland. This is something I have been a.ware of for 10
years and has been followed on a regular basis by my endocronologist. This finding does
not reveal any significant change in the microadenoma since my last MRI.
08199 – EKG – result:normal
09/20/99 – Median Nerve Evoked Potential – result: normal
09/20/99 – Posterior Tibial Evoked Response – result: normal
09/23/99 – MRI, cervical without contrast – result: normal
01/13/00 – Lumbar Puncture – result: borderline lyme serology. I t has been brought to
my attention that since a serum sample was not taken at the same time, this result is
irrelevant. I do not know why a serum sample was not ordered.

Thank you for your attention to this matter.
11.) CASE No. 11


I am a fifty-one year old woman who has survived Rheumatic Fever, Child birth
complications, a hysterectomy at the age of 27, and a three year bout with Lyme Disease
from 1987 to 1990. I have always been a fighter, and after each setback., I battled

my way back to a useful life.
This time is different. At the prompting of my insurance company and my
doctor, I received my first Lyme Vaccine shot on 5/4/99 and the second on
6/4/99. No one even thought to test me for a gene that would say I was
allergic to the shots. Suffering additional and increased health problems after the first two
shots, which included neuropathic pain in my legs and feet, migraines and other
headaches, severe sinus problems, chronic fatigue syndrome, depression, having to
double my medication (a Parkinsons drug called Mirapex) which was prescribed to me
for Restless :Leg Syndrome which began during my first bout with Lymes, I again took
the advice of my physician and got the third Lyme Vaccine shot in June of 2000.

From this point things went very wrong extremely fast, and I was able to
put it all together, placing the blame where it belonged, on the vaccine
shots for Lyme disease. My emotions went crazy, causing uncontrolled crying
spells while I was in school where I am learning computers. I became
extremely co&.sed (Lyme victims call it brain fog) and had to drop two of
my classes..My Restless Leg Syndrome, mostly, up to this point, medication controlled
jerking of the legs when I relaxed, suddenly began causing severe insomnia, jerking
of my head and left hand, and muscle spasms in my legs that my medication
would not stop. Fearing Parkinson’s, I was evaluated by two therapists who
were concerned because of a noticeable facial tic as well as a neck jerking.

My doctor suspected a late sequela of late treated Lyme’s disease and put me
on Lorazepam to calm my nerves, which did help my nerves, but nothing else.
Althougtl de&ed the possibility that the vaccine shots could have caused
my problems, she did agree to give me 28 days of doxicycline on the chance that

it might stop the irreversible neurological damage I was suffering. I began
to feel much better, and have done quite well until the past month when. my
left knee, my lower back, hips and neck have once again begun causing me
pain. (I had been pain free for at least two years before I got these shots) Although I was
never able to recall many things from my first bout with Lymes, I have been perfectly
able to relearn, as my two Scholarships and 3.868 Grade Point Average prove, but now

my memory is beginning to fail me again. I am signed up for three classes this neti
semester, and am so af?aid that I won’t be able to complete them. I want so badly to be
independent, to get a job that I can do over the intemet where I could w,ork around the
physical limitations I already had from Lyme Disease, but the additional fatigue, physical
and mental limitations inflicted upon me from these Lyme vaccination shots are &e last
straw. Unless I can receive some serious and immediate help, I fear I may soon be of no
use to anyone. I beg you to stop these vaccines now! Don’t let anyone, especially
children, suffer from them ever again.
12.) CASE No 12
fri 19 jan 2001
to whom it may concen
my name is
had the 3 shot series of the lyme
vaccine. june 13 th, 2000 was shot 3 of 3. six days later on 19 june
2000 i woke up with swollen , tender, and painfull knees and both
quadracept leg muscles hurt. the night before i had no prolblem at all.

it just came from nowhere without any warning symptoms.
during the following month my legs became weak and i noticed my leg
muscles getting smaller.after a quadracept biopsy and leg nerve
conduction tests i was diagnosed with muscle atophy and demyelination of
the nerves.

Approximately 1 aug 2000 i woke up with excruiating pain in my left hip.
i was first diagnosed with hip tendonitis then avascular necrosis and
then with an arthritic hip. this was all done with x-rays and mri”s.
in Sept. 2000 my left knee became so painfull i was told to use a cane,
which is the only way i can move now.

i was using oxyconyin 20 mg twice a day with no affect on the pain. i am
now on percocet S/325 about 5 times a day, just to take the extreme pain
away from my body, but it has no affect on my hip and knee pain.
my history is that in 1991 i had arthritis, scoliosis, hemochromatosis.
degenerative spine ,and degenerative lumbar area with stenosis of L3/L4
vertebrea causing sciatica. all the conditions starting with 199 1 have
been under control and stabilized with nsaids(feldene) for arthritis,theraputic
phlebotomys for hemochromatosis, and gravity lumbar
traction for the sciatica. i have been on social security disability

since 1995. i am currently 62 years old.
when on S.S. disability i could not work ( i was an electronics teacher
for 30 years ),because of low back pain , sciatica, and constant
gravity lumbar traction. now , i have no quality of life. i get around
on the cane and my right leg with great pain. i am very depressed and
fear-full of what migth happen next to my body as i live alone. if my
right leg goes, im dead in the water.

thanks .-
MON 14:29 c
i__ b_.-A
. . .

Good afternoon, my’ name is
I am from Wenham Massachusetts, one of the most Lyme-endemic areas in the US. I am a
member of ActionLyme, advocating for Lyme patient rights and the

Lyme information
and support group in my community.
I work locally with schools, parents and Lyme patients to raise awareness
of Lyme disease in our area, and I have read through much of what has
been written on Lymerix, especially the material provided by the CDC and

I come before you today as a mother of two, a consumer, and a patient
advocate, with issues that have occurred to others and me as we carefully
review the material on this vaccine.

1 pose these issues in the form of questions and hope this committee
sees fit to pursue answers to these important questions and concerns
before more aggressive marketing of the vaccine is allowed, especially to
our children.

I am a layperson –not a scientist. However others and myself have read
material published by the government and SmithKline Beecham and we
recognize the disparity between real- world experience and the reality of
the trials used to study the safety of‘Lymerix vaccine. I am sure my
questions are those that might be asked by any mother living in a Lyme-
endemic area, I pose them to you here, today with hope you will consider
the answers to these troubling questions before Lymerix is marketed to
our children.

I. The case definition of Lyme disease used for the vaccine is different
than the definition the CDC instructs our physicians to use when
diagnosing and treating Lyme. Given this disparity, how can we have
confidence that the vaccine trials reflect true patient situations?

2. Many individuals I know have claimed adverse events after receiving
the Lymerix vaccine, yet have been told their reports are ulnconnected to
the vaccine. How can so many people have the same type of reaction
directly after being vaccinated with Lymerix without it being vaccine

3. My children and I have had Lyme disease. I have read literature stating
the Lyme infection may persist, possibly hidden, in human cells after a
patient has been treated. What attentions have the Lymerix vaccine
makers taken to assure previously infected patients will not be harmed by
their vaccine?

4. The children playing in the forests and along the beaches of our
Massachusettstowns have been exposed to Lyme disease since they
could crawl. What of the children who have not been diagnosed with

nJ ,‘zz/ol
YON 14: 30
Lyme but do indeed’harbor the infection? What effect would Lymerix
vaccination produce in these innocents?
With new reports of asymptomatic

Lyme disease now abounding, 1 would
like to ask SmithKline Beecham how this possibility has been accounted
for in the study of safety of Lymerix for pediatric use.

I urge the committee to be prudent while reviewing the safety of thisvaccine.
Thank you for allowing me this opportunity.
Page 20
From –
o. Nancy Cherry
Date: l/21/01
Time: 1:45:48 PM

January 2 1, 200 1
Dear, Nancy Cherry
I’m writing this in reply to my concerns about Lymerix.
1. Doctors don’t know how to handle the rash of side effects.
2. Doctors don’t want to feel their at fault for the vaccine causing effects.
3. Patients are suffering because doctors don’t want to deal with Lyme let alone the vaccine
14.) Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes
that elicits bactericidal antibody responses: Implications for vaccine development.
Vaccine. 2017 May 31;35(24):3178-3185. doi: 10.1016/j.vaccine.2017.04.079. Epub 2017 May 4.

Izac JR1, Oliver LD Jr1, Earnhart CG1, Marconi RT2.
Author information
Dept. Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, VA, United States.
Dept. Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, VA, United States. Electronic address:
The lipoprotein OspA is produced by the Lyme disease spirochetes primarily in unfed ticks. OspA production is down-regulated by the blood meal and it is not produced in mammals except for possible transient production during late stage infection in patients with Lyme arthritis. Vaccination with OspA elicits antibody (Ab) that can target spirochetes in the tick midgut during feeding and inhibit transmission to mammals. OspA was the primary component of the human LYMErix™ vaccine. LYMErix™ was available from 1998 to 2002 but then pulled from the market due to declining sales as a result of unsubstantiated concerns about vaccination induced adverse events and poor efficacy. It was postulated that a segment of OspA that shares sequence similarity with a region in human LFA-1 and may trigger putative autoimmune events. While evidence supporting such a link has not been demonstrated, most efforts to move forward with OspA as a vaccine component have sought to eliminate this region of concern. Here we identify an OspA linear epitope localized within OspA amino acid residues 221-240 (OspA221-240) that lacks the OspA region suggested to elicit autoimmunity. A peptide consisting of residues 221-240 was immunogenic in mice. Ab raised against OspA221-240 peptide surface labeled B. burgdorferi in IFAs and displayed potent Ab mediated-complement dependent bactericidal activity. BLAST analyses identified several variants of OspA221-240 and a closely related sequence in OspB. It is our hypothesis that integration of the OspA221-240 epitope into a multivalent-OspC based chimeric epitope based vaccine antigen (chimeritope) could result in a subunit vaccine that protects against Lyme disease through synergistic mechanisms.
15.) Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.
J Exp Med. 1996 Jan 1;183(1):271-5.

de Silva AM1, Telford SR 3rd, Brunet LR, Barthold SW, Fikrig E.
Author information
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8031, USA.
Borrelia burgdorferi, the spirochetal agent of Lyme disease, is transmitted by Ixodes ticks. A vaccine based on B. burgdorferi outer surface protein (Osp) A protects mice from spirochete infection. Here we report on the expression of OspA on spirochetes inside engorging ticks and relate OspA expression to antispirochetal immunity. Spirochetes in the gut of unfed nymphal ticks were stained by an OspA antibody, whereas in feeding ticks, the majority of spirochetes in the gut and salivary glands did not stain with the antibody. Thus, OspA was not expressed on most spirochetes during transmission from the vector to the vertebrate host. To examine the mechanism of protection afforded by OspA antibody, mice were passively immunized with OspA antibody at different times relative to tick attachment. When OspA antibody was administered to mice before or at the time of tick attachment, spirochetal development events in the vector, such as growth and salivary gland invasion, were blocked and the mice were protected from B. burgdorferi infection. When OspA antibody was administered to mice 48 h after tick attachment, spirochetes persisted in the nymphs and the mice were not protected despite the presence of circulating antibodies in the host as well as in the tick blood meal. Thus, OspA immunity appears to be effective only during a narrow window time at the beginning of the blood meal when antibodies bind to OspA-expressing spirochetes in the tick gut and block transmission from the vector to the host.
16.) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1303-8. Epub 2004 Jan 23.

Willett TA1, Meyer AL, Brown EL, Huber BT.
Author information
Department of Pathology, Tufts University School of Medicine, 150 Harrison Avenue, Boston, MA 02111, USA.
The antigenic component of a common Lyme disease vaccine is recombinant outer surface protein A (rOspA) of Borrelia burgdorferi (Bb), the causative agent of Lyme disease. Coincidentally, patients with chronic, treatment-resistant Lyme arthritis develop an immune response against OspA, whereas those with acute Lyme disease usually do not. Treatment-resistant Lyme arthritis occurs in a subset of Lyme arthritis patients and is linked to HLA.DRB1*0401 (DR4) and related alleles. Recent work from our laboratory identified T cell crossreactivity between epitopes of OspA and lymphocyte function-associated antigen 1alpha(L) chain (LFA-1alpha(L)) in these patients. We generated a form of rOspA, FTK-OspA, in which the LFA-1alpha(L)/rOspA crossreactive T cell epitope was mutated to reduce the possible risk of autoimmunity in genetically susceptible individuals. FTK-OspA did not stimulate human or mouse DR4-restricted, WT-OspA-specific T cells, whereas it did stimulate antibody responses specific for WT-OspA that were similar to mice vaccinated WT-OspA. We show here that the protective efficacy of FTK-OspA is indistinguishable from that of WT-OspA in vaccination trials, as both C3H/HeJ and BALB/c FTK-OspA-vaccinated mice were protected from Bb infection. These data demonstrate that this rOspA-derived vaccine lacking the predicted cross-reactive T cell epitope, but retaining the capacity to elicit antibodies against infection, is effective in generating protective immunity.
17.) Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
J Infect Dev Ctries. 2017 Jan 30;11(1):1-9. doi: 10.3855/jidc.7999.

Zhao H1, Bao FF, Liu A.
Author information
Kunming Medical University, Kunming, China.
Lyme borreliosis, caused by Borrelia burgdorferi sensu stricto in the United States and by several Borrelia species in Europe and Asia, has a great impact on the health of the global population. There are human vaccines available, such as the outer surface protein A (OspA) vaccine, but still more evidence is needed to verify its function. We investigated the safety, immunogenicity, and efficacy of adjuvanted or non-adjuvanted vaccines containing protective epitopes from Borrelia species OspA serotypes in healthy adults.
Seven electronic databases were searched for clinical trials involving vaccine of OspA, with outcome data on safety, immunogenicity, and efficacy. The meta-analysis method was used to compare all vaccination strategies at the same time.
Three relevant studies were identified. All were randomized controlled trials (RCTs) or quasi-RCTs. Meta-analysis shows that, compared with low dose, high dose comes with a higher IgG titer with overall effect size of 6.39. For the 30 µg dose, the geometric mean titer was 6918.31, which is statistically significant when compared with 0. With respect to safety, only soreness showed a relatively high incidence of 40% (p < 0.05 when compared with 0, while the other side effects were no difference compared with 0).
The OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified. Instead of stagnating or giving up, further research on improving the vaccine is needed. On the foundation of preliminary studies, we can attempt to develop new vaccines for human use.
18.) Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development.
Vet J. 2016 Dec;218:27-33. doi: 10.1016/j.tvjl.2016.11.001. Epub 2016 Nov 9.

Oliver LD Jr1, Earnhart CG1, Virginia-Rhodes D1, Theisen M2, Marconi RT3.
Author information
Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, 1112 East Clay Street, McGuire Hall Room 101, Richmond, VA 23298-0678, USA.
Department of Congenital Disorders, Statens Serum Institute, Copenhagen, Denmark.
Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, 1112 East Clay Street, McGuire Hall Room 101, Richmond, VA 23298-0678, USA. Electronic address:
OspC performs essential functions during the enzootic cycle of the Lyme disease (LD) spirochetes. In this study, the specificity of antibody (Ab) responses to OspC was profiled to define the antigenic determinants during infection and after vaccination. Several OspC variants or ‘types’ were screened with serum from SNAP4Dx C6 positive dogs and with serum from rabbits hyperimmunized with OspC proteins. The OspC type-specific nature of the Ab response revealed that variable domains of OspC are immunodominant during infection and upon vaccination. To assess the potential of OspC to elicit Ab in the context of a bacterin vaccine, OspC production in strains cultivated in vitro was assessed. Immunoblot and indirect immunofluorescent antibody analyses demonstrated that production is low and that only a subset of cells actively produces OspC in vitro, raising questions about the potential of bacterin vaccines to stimulate significant anti-OspC Ab responses. The specificity of the OspC Ab response in experimentally infected mice over time was assessed to determine if domains shielded in the OspC homodimer become accessible and stimulate Ab production as infection progresses. The results demonstrate that the OspC Ab response remains focused on surface exposed variable regions of the protein throughout infection. In contrast to some earlier studies, it is concluded that conserved domains of OspC, including the C7 or C10 domain, do not elicit significant Ab responses during infection or upon vaccination. Collectively, the results indicate that OspC diversity must be considered in vaccine design and in the interpretation of diagnostic assays that employ OspC as a diagnostic antigen.
19.) Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.
Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00306-16. doi: 10.1128/CVI.00306-16. Print 2017 Jan.

Edmondson DG1, Prabhakaran S1, Norris SJ1, Ullmann AJ2, Piesman J2, Dolan M2, Probst C3, Radzimski C3, Stöcker W3, Komorowski L4.
Author information
Department of Pathology & Laboratory Medicine, Medical School, University of Texas, Houston, Texas, USA.
Centers for Disease Control and Prevention, Division of Vector-Borne Disease, Fort Collins, Colorado, USA.
Institute of Experimental Immunology, Euroimmun AG, Lübeck, Germany.
Institute of Experimental Immunology, Euroimmun AG, Lübeck, Germany
Lyme borreliosis is caused by tick-transmitted spirochetes of the Borrelia burgdorferi sensu lato group and is the most common vector-borne disease in the United States and Europe. Outer surface protein C (OspC) is a 23-kDa outer surface lipoprotein expressed during spirochete transmission from the tick to the vertebrate host. In a previous study, we found that immunization with a recombinant disulfide-bridged dimeric form of OspC (D-OspC) stimulates increased antibody responses relative to immunization with commonly employed monomeric OspC. Here, we report that mice immunized with dimeric OspC proteins also exhibited enhanced protection against infection with the cognate B. burgdorferi strain. Mice were protected by four immunizations containing as little as 100 ng of dimeric OspC, suggesting that this form of the protein can induce protective immunity within a dose range reasonable for a human or veterinary vaccine. In contrast, monomeric OspC was only partially protective at much higher doses. IgG subclass analysis revealed that D-OspC-immunized animals mainly possessed anti-OspC-IgG1. In contrast, infected animals develop anti-OspC restricted to the IgG3 isotype. A subset of antibodies generated by dimeric OspC immunization did not recognize the monomeric variant, indicating that unique epitopes exist on the dimeric form. Moreover, monoclonal antibodies that recognized only dimeric OspC protected mice from B. burgdorferi challenge, whereas another monoclonal that recognized both immunogens was not protective. These studies suggest that this dimeric OspC presents distinctive epitopes that generate antibodies protective against B. burgdorferi infection and could be a useful vaccine component.
20.) Intentions to receive a potentially available Lyme disease vaccine in an urban sample.
Ther Adv Vaccines. 2016 Jan;4(1-2):3-14. doi: 10.1177/2051013616629881. Epub 2016 Jan 1.

Fogel J1, Kusz M2.
Author information
Department of Business Management, Brooklyn College of the City University of New York, 218A, 2900 Bedford Avenue, Brooklyn, NY 11210, USA.
Department of Biology, Brooklyn College, Brooklyn, NY, USA.
The only human Lyme disease vaccine of LYMErix was voluntarily removed from the market in the United States in 2002 for a number of reasons. A new human Lyme disease vaccine is currently being developed. We would like any future approved human Lyme disease vaccine to be of interest and marketable to consumers.
We surveyed 714 participants to determine variables associated with intentions to receive a Lyme disease vaccine. Predictor variables included demographics, protection motivational theory, Lyme disease knowledge, Lyme disease preventive behaviors, beliefs and perceived health.
We found in multivariate linear regression analyses that Asian/Asian American race/ethnicity (p < 0.001), South Asian race/ethnicity (p = 0.01) and coping appraisal variables of response efficacy (p < 0.001) and self-efficacy (p < 0.001) were each significantly associated with increased intentions. The belief that vaccines are typically not safe was significantly associated with decreased intentions (p = 0.03).
Asian/Asian American and South Asian race/ethnicities have a strong interest in receiving a Lyme disease vaccine. Although pharmaceutical companies may benefit by advertising a Lyme disease vaccine to Asian/Asian Americans and South Asians, marketers need to address and use approaches to interest those from other race/ethnicities. Also, marketers need to address the erroneous belief that vaccines are typically not safe in order to interest those with such beliefs to use a Lyme disease vaccine.


Produced by Dr. Jose Lapenta R. Dermatologist
Maracay Estado Aragua Venezuela 2.017
Telf: 02432327287-02432328571



Excellent article & resource by Dr. Lapenta.  For more on the Lyme Vaccine:   a number of young women who fell ill after their HPV vaccination, which seems to have stimulated a latent Lyme infection to reactivate.  Asymptomatic girls after receiving Gardasil activated dormant Bartonella which was confirmed by testing.

Dengue Vaccine Causing Severe Dengue

Vaccinated Filipino youth now at risk of getting severe dengue

Published November 30, 2017

After Sanofi Pasteur’s advisory on Dengvaxia, Dr Anthony Leachon says students who already got their dengue shots from DOH will live with the possibility of getting severe dengue ‘for the rest of their lives’.

SCHOOL-BASED IMMUNIZATION. A student from Parang Elementary School gets a shot of Dengvaxia, the world's first-ever dengue vaccine. File photo by Ben Nabong/Rappler

SCHOOL-BASED IMMUNIZATION. A student from Parang Elementary School gets a shot of Dengvaxia, the world’s first-ever dengue vaccine. File photo by Ben Nabong/Rappler

MANILA, Philippines – Health advocates once again slammed the Department of Health’s (DOH) school-based immunization program after Sanofi Pasteur said its dengue vaccine poses more risk for people who have no prior infection.

Dr Anthony Leachon, former president of the Philippine College of Physicians Foundation, said on Thursday, November 30, that Sanofi’s advisory against its own vaccine is alarming for thousands of Filipino schoolchildren who already received their Dengvaxia shots.

“We don’t know the status of 700,000 kids vaccinated in NCR (National Capital Region), Region 4-A (Calabarzon), [and Region] 3 (Central Luzon) since they were not tested [for] previous exposure to dengue virus. We advised Congress and Senate that mass vaccination is not advisable without a rigid selection process,” he said.

“It means some of them will develop severe dengue; we don’t know who. All of them will have to live with this possibility for the rest of their lives,” added Leachon, who has 20 years of experience in pharmaceutical medicine.

On Thursday, Sanofi said new analysis of 6 years’ worth of clinical data revealed Dengvaxia could lead to “more cases of severe disease” when administered on a person who had never been infected by dengue prior the vaccination.

Former health chief Janette Garin launched the dengue school-based immunization program for Grade 4 students in 3 regions in April 2016, just 4 months after the Philippines approved the sale of the world’s first dengue vaccine.

A whopping P3.5 billion was allocated for it by the administration of then President Benigno Aquino III.

But this was met by strong criticism from various health advocates, who questioned the DOH’s decision for mass vaccination when studies on Dengvaxia was still being conducted at the time. (READ: DOH denies dengue vaccine to blame for 11-year-old’s death)

Garin had dispelled the public’s fears over the dengue vaccine. But a year later, Sanofi issued its announcement that confirmed the apprehensions of health advocates.

Current DOH Secretary Francisco Duque III said their technical assistance office is now meeting with individual experts to determine how to proceed following Sanofi’s advisory.

But he assured the public that children’s safety is “paramount” and will be the main consideration in their decision.

Prior to Sanofi’s announcement, DOH officials under President Rodrigo Duterte’s term said they plan to expand the dengue immunization program in Central Visayas.

‘Scam of an experimental drug’

Former health undersecretary Susan Pineda Mercado took to Facebook to express her frustration over the “biggest government funded clinical-trial-masked-as-a-public-health-program scam of an experimental drug in the history of the DOH.”

“This was reckless and irresponsible from the start and the public was deceived into thinking this vaccine would protect children from dengue. The public health community has been outraged for over a year. Legal action is now necessary,” said Mercado.

House probe into the dengue vaccination program was conducted late last year, led by Quezon 4th District Representative Angelina Tan, health committee chairperson.

“We asked that there should be proper social preparation and precautionary/screening test should be done prior to vaccination,” said Tan.

Her committee’s recommendations were already submitted in December 2016 to the good government and public accountability panel, which has the power to investigate alleged wrongdoings of government agencies and officials.

Tan said she plans to speak to the House leadership on Monday, December 4, to follow up on action on her committee’s recommendations in view of Sanofi’s advisory. –


The Lyme vaccine also caused the exact same symptoms as Lyme disease.  For more:  New Lyme Vaccine Coming Soon. Caveat Empter – Buyer Beware!

The Future of Lyme Disease – Final Contagion Live Segment

 Contagion Live  Sept. 7, 2017  Approx. 10:30

Peter L. Salgo, MD: What are we looking for going forward 10 years from now? What is the future of Lyme disease management, whether or not it be testing improvements?

Robert C. Bransfield, MD, DLFAPA: I would think, eventually, you see a trend towards more DNA-based testing platforms that may evolve. I think, eventually, there would be better testing that would help. The question of vaccines, that has been something that people have been struggling with for a long time. One interesting thing is vaccines against ticks themselves, because there have been a lot of problems with the vaccines so far. I think that of those different things that are being considered, that’s probably the best option. So, it has been very hard to develop a vaccine. Just like a vaccine against the common cold. It may not be possible. I would love to see it happen.

Samuel Shor, MD, FACP: One of the major problems is, even if you have a good vaccine for Borrelia, what do you do about the co-infections? And more and more ticks are co-infected.

Leonard Sigal, MD: That’s why, going back to your anti-tick idea, there’s a wisdom commonly shared: the more erythema, the more redness and inflammation you develop at a tick bite site, the less likely you are to actually get infection.

Samuel Shor, MD, FACP: More robust immune response.

Leonard Sigal, MD: And so, that goes back to your comment. If you could come up with a tick saliva vaccine, not only would you cover Borrelia burgdorferi, but you’d also cover coinfections as well.

Robert C. Bransfield, MD, DLFAPA: And I also think there’s a trend towards looking in the microbiome— the tick microbiome, the human microbiome—and that’s part of disease. It’s not like you can ever just get rid of all infection in the body. It’s the microbiome that’s within us, and that’s, I think, becoming a broader area in psychiatry and general medicine with chronic illness: to look at chronic infections and the microbiome, and some of these infections are good for us.

Peter L. Salgo, MD: We’re going to get guideline changes going forward?

Patricia V. Smith: Yes. I think we need to get guideline changes, and the reason that we need to is because, even though I know the IDSA is coming out with their guidelines in early 2018, my understanding is they didn’t last time—and I’m guessing that they won’t this time—include anything for patients with chronic disease or post-treatment Lyme, whatever you want to call it. And so, that is very problematic, the same way with the CDC MMWR article. The way they have, in a little box in the side of the article, put in that they do not recommend any antibiotic treatment or IVIG treatment for chronic Lyme because, of course, we know chronic Lyme doesn’t exist. So, now you leave a whole plethora of patients out there without any kinds of options. They’re not allowed to have alternative medicine and they’re not allowed to have extended antibiotics, which are not alternative medicine. Tuberculosis patients get treated for 2 years with IV antibiotics.

Leonard Sigal, MD: And there’s a reason for that, Pat. There’s a reason for that, and that is the lack of really rigorous science in support of those approaches.

Patricia V. Smith: I agree with you.

Leonard Sigal, MD: What I’d like to see is cooperation between the 2 ends of the spectrum, proper studies.

Patricia V. Smith: I’m totally in favor of that.

Peter L. Salgo, MD: I need to stop right here. I’m going to go around and everybody is going to get a last word. You’re going to get it, too. Dr. Bransfield, start. This is your shot.

Robert C. Bransfield, MD, DLFAPA: So, William Osler, the father of medicine, once said, “To know syphilis is to know medicine.” But I think we could look at that in terms of Lyme disease, and to know Lyme disease, you really have to know not just medicine, but also psychiatry, entomology, epidemiology, immunology, psychoimmunology, rheumatology, and politics.

Leonard Sigal, MD: Throw cardiology in as well.

Robert C. Bransfield, MD, DLFAPA: And cardiology. You need a broad capability that’s beyond the training of most people. So, the big thing we have to add is some humility. We can’t have arrogance. We have to know that a lot of the answers to this are outside our field of specialty, so we have to have open dialogue, open communication like we’re having here, and that’s what will help resolve this.

Peter L. Salgo, MD: Dr. Shor?

Samuel Shor, MD, FACP: Well, it’s important, I think, to recognize that chronic active Borrelia infection exists. What is most contentious is this post-treatment component, which I’ll get to in a second. But what is often disregarded are those who never get diagnosed and are untreated. We have an expanding tick population, and the percentage of ticks are increasing that are actually infected. The majority of patients never recognize they’ve been bitten by a tick. There’s a large percentage of them who don’t have the hallmark feature EM rash, and if they do, it’s often in a hidden place, or it may be atypical. They present with common symptoms—summer flu. Then, throw in the post-treatment group that can potentially present in similar manners with chronic disease. We’ve already alluded to that there’s good evidence of persistence after requisite antibiotics. Not everybody who’s chronically ill after treatment has active infection, but I would argue that a modest percentage do. And so, we need to be empathetic in dealing with this chronic fatigue, chronic pain, and cognitive impairment, this complex group of individuals who, unfortunately, because of poor lab testing and the politicization of this condition, are often peripheralized.

Peter L. Salgo, MD: Dr. Sigal?

Leonard Sigal, MD: In clinical medicine, have an open mind and an open heart. To rephrase what you were saying, we have to have humility, absolutely. We don’t know everything. We have to be open to the possibilities of it being Lyme disease, being another infection, being something else entirely, being immune meditated or inflammatory mediated. You have to be aware of all the potential mechanisms, and you have to be humble in the sight of all these competing potentials. You have to have an open mind and ultimately, even if I can’t make a diagnosis, the person who’s sitting in front of me is suffering. And to show that person the door without any sense of what we’re going to do next is cruel and should not be the practice of any physician. So, an open mind, open heart, clinical practice, and better science. We need to stop arguing with each other, and we need to stop pointing fingers, and we need to be able to move on and say, ultimately, that the only important thing is the patients are suffering. Ergo, I agree: power, I agree; money, I agree. We have to throw out those things and get beyond ourselves and sit down and come up with the studies, mutually agreeable studies, that will allow us to come up with biomarkers; better sero-confirmatory tests, they’re not diagnostic tests; and better approaches to therapy. Anything short of that is an abdication of our primary responsibility, which is to practice scientific and empathic medicine.

Peter L. Salgo, MD: And I promised you the last word.

Patricia V. Smith: You did.

Peter L. Salgo, MD: And I’m keeping my promise. Go ahead.

Patricia V. Smith: I want to speak to the fact that, for many decades now, patients and advocates have been left out of this process of Lyme disease. And by that I meant they’ve been excluded. Other diseases have had committees for years that have sat in Washington, and they’ve sat with these working groups, and they’ve been able to have input on their diseases. Patients have been totally excluded. It’s very frustrating for them. It has caused, in my opinion, some of this bad science, because the educated patients know what kind of studies they need to help them with their disease. They just want to get better. They don’t care about these arguments, they want to get better. They’ve never been able to sit down like this.

So, finally, I’m pleased to say that last year we were successful for the first time, after a lot of opposition from the IDSA and others over the years, in getting legislation passed and included in the 21st Century Cures Act. That provides a working group that—there’s a working group now in Washington—only includes federal officials at the table. They have been making all the decisions for patients. That is really outrageous. And so now, patients, because of the way we set this up, will have a seat at the table, perhaps an advocate, or a member of a Lyme organization will have a seat. Our treating physicians who have never had any input into this process—guess what they’re going to be doing. They’re going to be working with all the different agencies to find out what the resources are that are available for research, what kinds of studies need to be done, and it’s also going to be done in a transparent fashion, whereas now it’s behind closed doors. No one knows what research is selected until after it’s done, and then you have no say in the matter. I just say for Lyme patients, the time has come when they will get a seat at the table, to be able to have input about their disease.

Peter L. Salgo, MD: Alright. Well, thank you all for being here. You can all take off your flak jackets and your helmets. This has been a tremendous discussion, one of the best in my career, and I’m glad we all got at the same place at the same time to discuss what has been one of the most contentious issues in modern American medicine. On behalf of our panel, I want to thank you for joining us, and I hope you found this Peer Exchange® discussion to be useful and informative. I’m Dr. Peter Salgo, and I’ll see you next time.

The entire Contagion Live Series:
3rd Segment:  
7th Segment:  
8th Segment: